The	O
idea	O
that	O
the	O
customer	O
is	O
always	O
right	O
is	O
gospel	O
in	O
most	O
areas	O
of	O
business.	O
	
Most,	O
you	O
might	O
think,	O
except	O
the	O
business	O
of	O
making	O
drugs	B-KP
and	O
vaccines.	B-KP
	
Not	O
so.	O
	
The	O
cautionary	O
tale	O
of	O
the	O
Lyme-disease	B-KP
vaccine	I-KP
is	O
a	O
good	O
example	O
of	O
how	O
consumer	O
power	O
can	O
override	O
science.\nLyme	O
disease	I-KP
is	O
a	O
debilitating	O
infection	B-KP
spread	O
by	O
bites	O
from	O
ticks.	O
	
Found	O
mainly	O
in	O
the	O
United	O
States	O
and	O
Europe,	O
its	O
prevalence	O
is	O
increasing	O
as	O
civilization	O
encroaches	O
on	O
forested	O
areas	O
—	O
home	O
to	O
the	O
deer	O
on	O
which	O
the	O
ticks	O
feed.	O
	
A	O
vaccine	B-KP
is	O
badly	O
needed	O
to	O
contain	O
the	O
disease,	O
but	O
the	O
one	O
jab	O
available	O
was	O
pulled	O
from	O
the	O
market	O
after	O
complaints	O
from	O
a	O
group	O
of	O
patients	O
damaged	O
its	O
reputation.	O
	
Now,	O
a	O
similar	O
vaccine	B-KP
is	O
set	O
to	O
emerge,	O
but	O
some	O
say	O
it	O
has	O
been	O
tweaked	O
in	O
a	O
way	O
that	O
confers	O
no	O
obvious	O
scientific	O
benefit.	O
	
Lyme	B-KP
disease	I-KP
made	O
a	O
meteoric	O
entry	O
into	O
medical	O
and	O
public	O
consciousness	O
30	O
years	O
ago,	O
when	O
Allen	O
Steere,	O
a	O
rheumatologist	O
now	O
at	O
Massachusetts	O
General	O
Hospital	O
in	O
Boston,	O
described	O
an	O
outbreak	O
of	O
a	O
mysterious	O
illness	O
in	O
Lyme,	O
Connecticut.	O
	
The	O
disease	O
he	O
identified	O
was	O
caused	O
by	O
a	O
spirochete,	B-KP
a	O
spiral-shaped	B-KP
bacterium	I-KP
called	O
Borrelia	B-KP
burgdorferi.	I-KP
	
It	O
is	O
rarely	O
fatal,	O
but	O
acute	O
infection	O
results	O
in	O
a	O
range	O
of	O
unpleasant	O
and	O
debilitating	O
symptoms,	O
including	O
flu-like	O
effects,	O
a	O
bullseye	B-KP
rash	I-KP
and	O
neurological	B-KP
problems	I-KP
such	O
as	O
facial	B-KP
palsy.	I-KP
	
After	O
several	O
weeks	O
without	O
treatment,	O
some	O
patients	O
go	O
on	O
to	O
develop	O
joint	B-KP
pain	I-KP
or	O
arthritis.	B-KP
	
If	O
left	O
untreated,	O
it	O
can	O
last	O
for	O
years,	O
but	O
even	O
then	O
will	O
usually	O
respond	O
to	O
antibiotics.	B-KP
	
In	O
a	O
small	O
subset	O
of	O
patients,	O
however,	O
the	O
joint	O
pain	O
and	O
swelling	O
do	O
not	O
respond	O
—	O
the	O
condition	O
is	O
known	O
as	O
treatment-resistant	B-KP
Lyme	I-KP
arthritis.	I-KP
	
It	O
was	O
arguments	O
about	O
the	O
long-term	O
persistence	O
of	O
Lyme	B-KP
disease	I-KP
that	O
triggered	O
the	O
first	O
'Lyme	O
scandal’.	O
	
In	O
the	O
1990s,	O
Steere	O
was	O
hounded	O
by	O
patients	O
who	O
claimed	O
to	O
be	O
suffering	O
from	O
a	O
chronic	O
form	O
of	O
Lyme	B-KP
disease	I-KP
that	O
left	O
them	O
persistently	O
exhausted.	O
	
Steere	O
insisted	O
that	O
they	O
had	O
been	O
misdiagnosed.	O
	
Although	O
the	O
patients	O
had	O
antibodies	B-KP
to	O
Lyme	B-KP
disease,	I-KP
indicating	O
that	O
they	O
had	O
at	O
one	O
time	O
been	O
exposed	O
to	O
Borrelia,	B-KP
Steere	O
maintained	O
that	O
their	O
range	O
of	O
vague	O
symptoms	O
did	O
not	O
correlate	O
with	O
the	O
true	O
course	O
of	O
the	O
disease.	O
	
He	O
says	O
he	O
wanted	O
to	O
save	O
people	O
from	O
unnecessary	O
antibiotic	B-KP
treatment,	I-KP
but	O
instead	O
found	O
himself	O
under	O
protection	O
of	O
security	O
guards,	O
and	O
dealing	O
with	O
hate	O
mail	O
and	O
even	O
death	O
threats.	O
	
The	O
idea	O
that	O
the	O
customer	O
is	O
always	O
right	O
is	O
gospel	O
in	O
most	O
areas	O
of	O
business.	O
	
Most,	O
you	O
might	O
think,	O
except	O
the	O
business	O
of	O
making	O
drugs	B-KP
and	O
vaccines.	B-KP
	
Not	O
so.	O
	
The	O
cautionary	O
tale	O
of	O
the	O
Lyme-disease	B-KP
vaccine	I-KP
is	O
a	O
good	O
example	O
of	O
how	O
consumer	O
power	O
can	O
override	O
science.\nLyme	O
disease	I-KP
is	O
a	O
debilitating	O
infection	B-KP
spread	O
by	O
bites	O
from	O
ticks.	O
	
Found	O
mainly	O
in	O
the	O
United	O
States	O
and	O
Europe,	O
its	O
prevalence	O
is	O
increasing	O
as	O
civilization	O
encroaches	O
on	O
forested	O
areas	O
—	O
home	O
to	O
the	O
deer	O
on	O
which	O
the	O
ticks	O
feed.	O
	
A	O
vaccine	B-KP
is	O
badly	O
needed	O
to	O
contain	O
the	O
disease,	O
but	O
the	O
one	O
jab	O
available	O
was	O
pulled	O
from	O
the	O
market	O
after	O
complaints	O
from	O
a	O
group	O
of	O
patients	O
damaged	O
its	O
reputation.	O
	
Now,	O
a	O
similar	O
vaccine	B-KP
is	O
set	O
to	O
emerge,	O
but	O
some	O
say	O
it	O
has	O
been	O
tweaked	O
in	O
a	O
way	O
that	O
confers	O
no	O
obvious	O
scientific	O
benefit.	O
	
Lyme	B-KP
disease	I-KP
made	O
a	O
meteoric	O
entry	O
into	O
medical	O
and	O
public	O
consciousness	O
30	O
years	O
ago,	O
when	O
Allen	O
Steere,	O
a	O
rheumatologist	O
now	O
at	O
Massachusetts	O
General	O
Hospital	O
in	O
Boston,	O
described	O
an	O
outbreak	O
of	O
a	O
mysterious	O
illness	O
in	O
Lyme,	O
Connecticut.	O
	
The	O
disease	O
he	O
identified	O
was	O
caused	O
by	O
a	O
spirochete,	B-KP
a	O
spiral-shaped	B-KP
bacterium	I-KP
called	O
Borrelia	B-KP
burgdorferi.	I-KP
	
It	O
is	O
rarely	O
fatal,	O
but	O
acute	O
infection	O
results	O
in	O
a	O
range	O
of	O
unpleasant	O
and	O
debilitating	O
symptoms,	O
including	O
flu-like	O
effects,	O
a	O
bullseye	B-KP
rash	I-KP
and	O
neurological	B-KP
problems	I-KP
such	O
as	O
facial	B-KP
palsy.	I-KP
	
After	O
several	O
weeks	O
without	O
treatment,	O
some	O
patients	O
go	O
on	O
to	O
develop	O
joint	B-KP
pain	I-KP
or	O
arthritis.	B-KP
	
If	O
left	O
untreated,	O
it	O
can	O
last	O
for	O
years,	O
but	O
even	O
then	O
will	O
usually	O
respond	O
to	O
antibiotics.	B-KP
	
In	O
a	O
small	O
subset	O
of	O
patients,	O
however,	O
the	O
joint	O
pain	O
and	O
swelling	O
do	O
not	O
respond	O
—	O
the	O
condition	O
is	O
known	O
as	O
treatment-resistant	B-KP
Lyme	I-KP
arthritis.	I-KP
	
It	O
was	O
arguments	O
about	O
the	O
long-term	O
persistence	O
of	O
Lyme	B-KP
disease	I-KP
that	O
triggered	O
the	O
first	O
'Lyme	O
scandal’.	O
	
In	O
the	O
1990s,	O
Steere	O
was	O
hounded	O
by	O
patients	O
who	O
claimed	O
to	O
be	O
suffering	O
from	O
a	O
chronic	O
form	O
of	O
Lyme	B-KP
disease	I-KP
that	O
left	O
them	O
persistently	O
exhausted.	O
	
Steere	O
insisted	O
that	O
they	O
had	O
been	O
misdiagnosed.	O
	
Although	O
the	O
patients	O
had	O
antibodies	B-KP
to	O
Lyme	B-KP
disease,	I-KP
indicating	O
that	O
they	O
had	O
at	O
one	O
time	O
been	O
exposed	O
to	O
Borrelia,	B-KP
Steere	O
maintained	O
that	O
their	O
range	O
of	O
vague	O
symptoms	O
did	O
not	O
correlate	O
with	O
the	O
true	O
course	O
of	O
the	O
disease.	O
	
He	O
says	O
he	O
wanted	O
to	O
save	O
people	O
from	O
unnecessary	O
antibiotic	B-KP
treatment,	I-KP
but	O
instead	O
found	O
himself	O
under	O
protection	O
of	O
security	O
guards,	O
and	O
dealing	O
with	O
hate	O
mail	O
and	O
even	O
death	O
threats.	O
	
In	O
recent	O
years,	O
species	O
ofBorrelia	B-KP
have	O
been	O
recognized	O
asthe	O
etiologic	I-KP
agents	O
ofseveral	O
apparently	O
diverse	O
diseases,	O
including	O
erythema	I-KP
chronicum	I-KP
migrans	O
(ECM);	O
Lyme	I-KP
disease	O
(LD);	O
acrodermatitis	I-KP
chronica	I-KP
atrophicans	O
(ACA);	O
lymphadenosis	I-KP
benigna	I-KP
cutis	O
(LBC),	O
originally	O
called	O
Spiegler-Fendt	I-KP
sarcoid;	O
and	O
possibly	O
some	O
types	O
ofmorphea,	B-KP
lichen	I-KP
sclerosus	I-KP
et	I-KP
atrophicus	O
(LSA),	O
progressive	I-KP
facial	I-KP
hemiatrophyofParry-Romberg(PFH),	O
benign	I-KP
lymphocytic	I-KP
infiltrate	I-KP
of	I-KP
the	I-KP
skin	O
(Jessner-Kanof)	O
(BLI),	O
and	B-KP
Shulman	I-KP
syndrome	O
(eosinophilic	I-KP
fasciitis).	O
	
Lyme	I-KP
disease	O
was	O
reviewed	O
in	O
Part	O
I	O
of	O
this	O
series.	O
	
[1]	B-KP
ACA,	B-KP
LBC,	B-KP
LSA,	B-KP
PFH,	B-KP
BLI,	O
and	I-KP
Shulman	I-KP
syndrome	O
have	O
been	O
linked	O
in	O
varying	O
degrees	O
with	B-KP
borreliae	O
and	O
are	O
the	O
subject	O
of	O
this	O
review.	O
	
In	O
recent	O
years,	O
species	O
ofBorrelia	B-KP
have	O
been	O
recognized	O
asthe	O
etiologic	I-KP
agents	O
ofseveral	O
apparently	O
diverse	O
diseases,	O
including	O
erythema	I-KP
chronicum	I-KP
migrans	O
(ECM);	O
Lyme	I-KP
disease	O
(LD);	O
acrodermatitis	I-KP
chronica	I-KP
atrophicans	O
(ACA);	O
lymphadenosis	I-KP
benigna	I-KP
cutis	O
(LBC),	O
originally	O
called	O
Spiegler-Fendt	I-KP
sarcoid;	O
and	O
possibly	O
some	O
types	O
ofmorphea,	B-KP
lichen	I-KP
sclerosus	I-KP
et	I-KP
atrophicus	O
(LSA),	O
progressive	I-KP
facial	I-KP
hemiatrophyofParry-Romberg(PFH),	O
benign	I-KP
lymphocytic	I-KP
infiltrate	I-KP
of	I-KP
the	I-KP
skin	O
(Jessner-Kanof)	O
(BLI),	O
and	B-KP
Shulman	I-KP
syndrome	O
(eosinophilic	I-KP
fasciitis).	O
	
Lyme	I-KP
disease	O
was	O
reviewed	O
in	O
Part	O
I	O
of	O
this	O
series.	O
	
[1]	B-KP
ACA,	B-KP
LBC,	B-KP
LSA,	B-KP
PFH,	B-KP
BLI,	O
and	I-KP
Shulman	I-KP
syndrome	O
have	O
been	O
linked	O
in	O
varying	O
degrees	O
with	B-KP
borreliae	O
and	O
are	O
the	O
subject	O
of	O
this	O
review.	O
	
Lyme	B-KP
disease	I-KP
can	O
be	O
classified	O
using	O
the	O
terminology	O
of	O
syphilis.	B-KP
	
In	O
this	O
series	O
of	O
95	O
cases	O
from	O
the	O
upper	O
midwest,	O
early	O
cases,	O
defined	O
as	O
an	O
illness	O
of	O
<2	O
months,	O
were	O
more	O
likely	O
to	O
have	O
lived	O
in	O
or	O
recently	O
visited	O
a	O
highly	O
endemic	B-KP
area.	I-KP
	
Unlike	O
late	O
cases,	O
early	O
cases	O
presented	O
entirely	O
in	O
the	O
nonwinter	O
months	O
(p	O
<	O
.001).	O
	
Early	O
disease	O
was	O
further	O
subdivided	O
into	O
primary	B-KP
and	I-KP
secondary	I-KP
disease.	I-KP
	
Ninety	O
percent	O
of	O
primary	O
and	O
43%	O
of	O
secondary	O
cases	O
had	O
erythema	B-KP
migrans,	I-KP
while	O
no	O
late	O
cases	O
had	O
active	O
erythema	B-KP
migrans	I-KP
(p	O
<	O
.001).	O
	
Clinical	B-KP
manifestations	I-KP
of	I-KP
nonspecific	I-KP
inflammation,	I-KP
except	O
for	O
arthralgia,	B-KP
were	O
more	O
common	O
in	O
early	O
than	O
late	O
disease	O
(p	O
<	O
.01).	O
	
In	O
secondary	O
cases,	O
monoarticular	B-KP
arthritis	I-KP
was	O
slightly	O
more	O
common	O
than	O
polyarticular	B-KP
arthritis,	I-KP
with	O
the	O
reverse	O
occurring	O
in	O
late	O
disease	O
(p	O
<	O
.05).	O
	
Indirect	B-KP
fluorescent	I-KP
antibody	I-KP
testing	I-KP
revealed	O
a	O
ratio	O
of	O
IgM	B-KP
to	O
IgG	B-KP
antibodies	I-KP
to	O
be	O
helpful	O
in	O
distinguishing	O
early	O
from	O
late	O
disease.	O
	
Antibacterial	B-KP
therapy	I-KP
in	O
early,	O
primary	O
cases	O
caused	O
Jarisch-Herxheimer	B-KP
reaction	O
7%	O
of	O
the	O
time.	O
	
Despite	O
longer	O
and	O
more	O
frequent	O
parenteral	O
therapy,	O
late	O
Lyme	B-KP
disease	I-KP
frequently	O
required	O
retreatment,	O
owing	O
to	O
poor	O
clinical	O
response	O
(p	O
<	O
.05).	O
	
Lyme	B-KP
disease	I-KP
can	O
be	O
classified	O
using	O
the	O
terminology	O
of	O
syphilis.	B-KP
	
In	O
this	O
series	O
of	O
95	O
cases	O
from	O
the	O
upper	O
midwest,	O
early	O
cases,	O
defined	O
as	O
an	O
illness	O
of	O
<2	O
months,	O
were	O
more	O
likely	O
to	O
have	O
lived	O
in	O
or	O
recently	O
visited	O
a	O
highly	O
endemic	B-KP
area.	I-KP
	
Unlike	O
late	O
cases,	O
early	O
cases	O
presented	O
entirely	O
in	O
the	O
nonwinter	O
months	O
(p	O
<	O
.001).	O
	
Early	O
disease	O
was	O
further	O
subdivided	O
into	O
primary	B-KP
and	I-KP
secondary	I-KP
disease.	I-KP
	
Ninety	O
percent	O
of	O
primary	O
and	O
43%	O
of	O
secondary	O
cases	O
had	O
erythema	B-KP
migrans,	I-KP
while	O
no	O
late	O
cases	O
had	O
active	O
erythema	B-KP
migrans	I-KP
(p	O
<	O
.001).	O
	
Clinical	B-KP
manifestations	I-KP
of	I-KP
nonspecific	I-KP
inflammation,	I-KP
except	O
for	O
arthralgia,	B-KP
were	O
more	O
common	O
in	O
early	O
than	O
late	O
disease	O
(p	O
<	O
.01).	O
	
In	O
secondary	O
cases,	O
monoarticular	B-KP
arthritis	I-KP
was	O
slightly	O
more	O
common	O
than	O
polyarticular	B-KP
arthritis,	I-KP
with	O
the	O
reverse	O
occurring	O
in	O
late	O
disease	O
(p	O
<	O
.05).	O
	
Indirect	B-KP
fluorescent	I-KP
antibody	I-KP
testing	I-KP
revealed	O
a	O
ratio	O
of	O
IgM	B-KP
to	O
IgG	B-KP
antibodies	I-KP
to	O
be	O
helpful	O
in	O
distinguishing	O
early	O
from	O
late	O
disease.	O
	
Antibacterial	B-KP
therapy	I-KP
in	O
early,	O
primary	O
cases	O
caused	O
Jarisch-Herxheimer	B-KP
reaction	O
7%	O
of	O
the	O
time.	O
	
Despite	O
longer	O
and	O
more	O
frequent	O
parenteral	O
therapy,	O
late	O
Lyme	B-KP
disease	I-KP
frequently	O
required	O
retreatment,	O
owing	O
to	O
poor	O
clinical	O
response	O
(p	O
<	O
.05).	O
	
For	O
patients	O
in	O
category	O
1,	O
proper	O
care	O
needs	O
to	O
be	O
practiced	O
when	O
removing	O
ticks,	O
especially	O
the	O
Ixodes	B-KP
genus,	I-KP
from	O
the	O
skin.	B-KP
	
It	O
is	O
often	O
difficult	O
to	O
definitively	O
identify	O
a	O
tick	O
as	O
I.	B-KP
	
scapularis	I-KP
in	O
the	O
ED;	B-KP
however,	O
in	O
endemic	B-KP
areas	I-KP
with	O
high	O
LD	B-KP
prevalence	O
or	O
in	O
cases	O
where	O
there	O
is	O
high	O
clinical	O
suspicion	O
for	O
tick	O
exposure,	O
emergency	O
physicians	O
should	O
evaluate	O
and	O
treat	O
patients	O
with	O
the	O
assumption	O
that	O
the	O
tick	O
is	O
I.	B-KP
	
scapularis	I-KP
and	O
consider	O
sending	O
the	O
tick	O
for	O
pathology	B-KP
identification.	I-KP
	
Ixodes	B-KP
ticks	I-KP
cement	O
their	O
mouth	O
parts	O
into	O
the	O
skin	O
with	O
secretions	O
from	O
their	O
salivary	O
glands	O
and	O
have	O
specialized	O
structures	O
for	O
holding	O
them	O
in	O
the	O
skin	O
while	O
the	O
tick	O
feeds.	O
	
Attached	O
ticks	O
should	O
be	O
removed	O
with	O
fine-tip	O
forceps.	O
	
Any	O
portion	O
of	O
the	O
mouth	O
parts	O
of	O
the	O
tick	O
still	O
embedded	O
in	O
the	O
skin	O
need	O
not	O
be	O
removed	O
and	O
only	O
disinfected,	O
for	O
there	O
is	O
no	O
risk	O
of	O
LD	B-KP
and	O
the	O
removal	O
can	O
cause	O
unnecessary	O
tissue	O
damage.	O
	
Use	O
of	O
hot	O
objects,	O
such	O
as	O
matches,	O
is	O
contraindicated	O
and	O
may	O
induce	O
regurgitation	O
and	O
cause	O
infected	O
fluids	O
to	O
enter	O
the	O
wound	O
(44).	O
	
For	O
patients	O
in	O
category	O
1,	O
proper	O
care	O
needs	O
to	O
be	O
practiced	O
when	O
removing	O
ticks,	O
especially	O
the	O
Ixodes	B-KP
genus,	I-KP
from	O
the	O
skin.	B-KP
	
It	O
is	O
often	O
difficult	O
to	O
definitively	O
identify	O
a	O
tick	O
as	O
I.	B-KP
	
scapularis	I-KP
in	O
the	O
ED;	B-KP
however,	O
in	O
endemic	B-KP
areas	I-KP
with	O
high	O
LD	B-KP
prevalence	O
or	O
in	O
cases	O
where	O
there	O
is	O
high	O
clinical	O
suspicion	O
for	O
tick	O
exposure,	O
emergency	O
physicians	O
should	O
evaluate	O
and	O
treat	O
patients	O
with	O
the	O
assumption	O
that	O
the	O
tick	O
is	O
I.	B-KP
	
scapularis	I-KP
and	O
consider	O
sending	O
the	O
tick	O
for	O
pathology	B-KP
identification.	I-KP
	
Ixodes	B-KP
ticks	I-KP
cement	O
their	O
mouth	O
parts	O
into	O
the	O
skin	O
with	O
secretions	O
from	O
their	O
salivary	O
glands	O
and	O
have	O
specialized	O
structures	O
for	O
holding	O
them	O
in	O
the	O
skin	O
while	O
the	O
tick	O
feeds.	O
	
Attached	O
ticks	O
should	O
be	O
removed	O
with	O
fine-tip	O
forceps.	O
	
Any	O
portion	O
of	O
the	O
mouth	O
parts	O
of	O
the	O
tick	O
still	O
embedded	O
in	O
the	O
skin	O
need	O
not	O
be	O
removed	O
and	O
only	O
disinfected,	O
for	O
there	O
is	O
no	O
risk	O
of	O
LD	B-KP
and	O
the	O
removal	O
can	O
cause	O
unnecessary	O
tissue	O
damage.	O
	
Use	O
of	O
hot	O
objects,	O
such	O
as	O
matches,	O
is	O
contraindicated	O
and	O
may	O
induce	O
regurgitation	O
and	O
cause	O
infected	O
fluids	O
to	O
enter	O
the	O
wound	O
(44).	O
	
Serum	B-KP
samples	I-KP
were	O
tested	O
for	O
evidence	O
of	O
infection	O
by	O
the	O
agents	O
of	O
Lyme	B-KP
disease	I-KP
(B.	B-KP
	
burgdorferi),	O
human	I-KP
monocytic	I-KP
ehrlichiosis	I-KP
(Ehrlichia	B-KP
chaffeensis),	O
human	I-KP
granulocytic	I-KP
ehrlichiosis	I-KP
(Ehrlichia	B-KP
phagocytophila),	O
Rocky	I-KP
Mountain	I-KP
spotted	I-KP
fever	I-KP
(Rickettsia	B-KP
rickettsii),	O
murine	I-KP
typhus	I-KP
(Rickettsia	B-KP
typhi),	O
Q	I-KP
fever	I-KP
(Coxiella	B-KP
burneti),	O
tularaemia	I-KP
(Francisella	B-KP
tularensis)	O
and	O
babesiosis	I-KP
(Babesia	B-KP
microti).	O
	
IgG	I-KP
antibodies	I-KP
against	O
antigens	I-KP
of	I-KP
E.	I-KP
	
chaffeensis,	O
E.	I-KP
	
phagocytophila,	O
R.	I-KP
	
rickettsii,	O
R.	I-KP
	
typhi,	O
C.	I-KP
	
burneti,	O
and	O
B.	I-KP
	
microti	I-KP
were	O
tested	O
by	O
indirect	I-KP
fluorescent	I-KP
antibody	I-KP
assays	I-KP
(IFA),	B-KP
as	O
previously	O
described	O
(11–14).	O
	
The	O
serum	O
samples	O
were	O
screened	O
against	O
F.	I-KP
	
tularensis	I-KP
by	O
an	O
agglutination	I-KP
assay,	O
according	O
to	O
the	O
manufacturer’s	O
recommendations	O
(Difco	O
Laboratories,	O
Detroit,	O
MI,	O
USA).\nIgG	O
antibodies	I-KP
against	O
the	O
Lyme	I-KP
disease	I-KP
spirochaete	I-KP
were	O
initially	O
detected	O
by	O
enzyme-linked	I-KP
immunosorbent	I-KP
assay	I-KP
(ELISA)	B-KP
using	O
antigens	I-KP
of	O
the	O
N40	I-KP
strain	I-KP
of	I-KP
B.	I-KP
	
burgdorferi	I-KP
sensu	I-KP
stricto	I-KP
(15).	O
	
Briefly,	O
low-passage	O
wildtype	O
N40	O
was	O
harvested	O
at	O
log-phase	O
growth,	O
washed	O
three	O
times	O
in	O
Hanks'	I-KP
balanced	I-KP
salt	I-KP
solution	I-KP
(HBSS),	B-KP
and	O
resuspended	O
in	O
20	O
times	O
the	O
original	O
culture	O
volume	O
in	O
HBSS.	O
	
The	O
washed	O
spirochaetes	I-KP
were	O
sonicated	O
on	O
ice	O
until	O
darkfield	O
microscopy	O
indicated	O
that	O
>85%	O
of	O
the	O
organisms	O
had	O
been	O
disrupted.	O
	
After	O
centrifugation	O
to	O
remove	O
fragments	O
and	O
whole	O
spirochaetes,	O
the	O
soluble	O
extract	O
was	O
aliquoted	O
and	O
stored	O
at	O
–20C.	O
	
Microtitre	O
plates	O
(Immulon	O
4,	O
Dynex,	O
Chantilly,	O
VA,	O
USA)	O
were	O
coated	O
with	O
250	O
mg	O
of	O
antigen	I-KP
per	O
well	O
and	O
allowed	O
to	O
dry.	O
	
The	O
plates	O
were	O
blocked	O
with	O
5%	O
donor	O
horse	O
serum,	O
1%	O
dextran	O
sulfate	O
in	O
PBS-Tween	O
20.	O
	
Sera	O
were	O
diluted	O
in	O
this	O
blocking	O
buffer	O
at	O
1:100,	O
added	O
to	O
wells	O
in	O
triplicate,	O
and	O
incubated	O
for	O
1	O
hour.	O
	
Bound	O
antibody	I-KP
was	O
detected	O
by	O
the	O
addition	O
of	O
alkaline	I-KP
phosphatase-conjugated	I-KP
goat	I-KP
antihuman	I-KP
IgG	I-KP
(Kirkegaard	O
&	O
Perry	O
Laboratories,	O
Gaithersburg,	O
MD,	O
USA),	O
as	O
recommended	O
by	O
the	O
manufacturer.	O
	
A	B-KP
p-nitrophenyl	I-KP
phosphate	I-KP
substrate	I-KP
in	I-KP
diethanolamine	I-KP
buffer	O
was	O
used	O
to	O
visualize	O
bound	O
secondary	I-KP
antibody	O
when	O
the	O
reactions	O
were	O
terminated	O
at	O
30	O
minutes,	O
and	O
read	O
promptly	O
at	O
l	O
=	O
405	O
nm.	O
	
Negative	O
control	O
sera	O
(n	O
=	O
6),	O
taken	O
from	O
laboratory	O
staff	O
members	O
with	O
no	O
history	O
of	B-KP
Lyme	I-KP
disease,	O
were	O
analysed	O
on	O
each	O
plate.	O
	
A	I-KP
serum	I-KP
sample	O
was	O
considered	O
reactive	O
if	O
its	O
mean	O
absorbance	O
exceeded	O
3	O
standard	O
deviations	O
of	O
the	O
mean	O
of	O
the	O
18	O
(6	O
x	O
3)	O
negative	O
control	O
wells,	O
calculated	O
for	O
each	O
microtitre	O
plate.	O
	
Serum	B-KP
samples	I-KP
were	O
tested	O
for	O
evidence	O
of	O
infection	O
by	O
the	O
agents	O
of	O
Lyme	B-KP
disease	I-KP
(B.	B-KP
	
burgdorferi),	O
human	I-KP
monocytic	I-KP
ehrlichiosis	I-KP
(Ehrlichia	B-KP
chaffeensis),	O
human	I-KP
granulocytic	I-KP
ehrlichiosis	I-KP
(Ehrlichia	B-KP
phagocytophila),	O
Rocky	I-KP
Mountain	I-KP
spotted	I-KP
fever	I-KP
(Rickettsia	B-KP
rickettsii),	O
murine	I-KP
typhus	I-KP
(Rickettsia	B-KP
typhi),	O
Q	I-KP
fever	I-KP
(Coxiella	B-KP
burneti),	O
tularaemia	I-KP
(Francisella	B-KP
tularensis)	O
and	O
babesiosis	I-KP
(Babesia	B-KP
microti).	O
	
IgG	I-KP
antibodies	I-KP
against	O
antigens	I-KP
of	I-KP
E.	I-KP
	
chaffeensis,	O
E.	I-KP
	
phagocytophila,	O
R.	I-KP
	
rickettsii,	O
R.	I-KP
	
typhi,	O
C.	I-KP
	
burneti,	O
and	O
B.	I-KP
	
microti	I-KP
were	O
tested	O
by	O
indirect	I-KP
fluorescent	I-KP
antibody	I-KP
assays	I-KP
(IFA),	B-KP
as	O
previously	O
described	O
(11–14).	O
	
The	O
serum	O
samples	O
were	O
screened	O
against	O
F.	I-KP
	
tularensis	I-KP
by	O
an	O
agglutination	I-KP
assay,	O
according	O
to	O
the	O
manufacturer’s	O
recommendations	O
(Difco	O
Laboratories,	O
Detroit,	O
MI,	O
USA).\nIgG	O
antibodies	I-KP
against	O
the	O
Lyme	I-KP
disease	I-KP
spirochaete	I-KP
were	O
initially	O
detected	O
by	O
enzyme-linked	I-KP
immunosorbent	I-KP
assay	I-KP
(ELISA)	B-KP
using	O
antigens	I-KP
of	O
the	O
N40	I-KP
strain	I-KP
of	I-KP
B.	I-KP
	
burgdorferi	I-KP
sensu	I-KP
stricto	I-KP
(15).	O
	
Briefly,	O
low-passage	O
wildtype	O
N40	O
was	O
harvested	O
at	O
log-phase	O
growth,	O
washed	O
three	O
times	O
in	O
Hanks'	I-KP
balanced	I-KP
salt	I-KP
solution	I-KP
(HBSS),	B-KP
and	O
resuspended	O
in	O
20	O
times	O
the	O
original	O
culture	O
volume	O
in	O
HBSS.	O
	
The	O
washed	O
spirochaetes	I-KP
were	O
sonicated	O
on	O
ice	O
until	O
darkfield	O
microscopy	O
indicated	O
that	O
>85%	O
of	O
the	O
organisms	O
had	O
been	O
disrupted.	O
	
After	O
centrifugation	O
to	O
remove	O
fragments	O
and	O
whole	O
spirochaetes,	O
the	O
soluble	O
extract	O
was	O
aliquoted	O
and	O
stored	O
at	O
–20C.	O
	
Microtitre	O
plates	O
(Immulon	O
4,	O
Dynex,	O
Chantilly,	O
VA,	O
USA)	O
were	O
coated	O
with	O
250	O
mg	O
of	O
antigen	I-KP
per	O
well	O
and	O
allowed	O
to	O
dry.	O
	
The	O
plates	O
were	O
blocked	O
with	O
5%	O
donor	O
horse	O
serum,	O
1%	O
dextran	O
sulfate	O
in	O
PBS-Tween	O
20.	O
	
Sera	O
were	O
diluted	O
in	O
this	O
blocking	O
buffer	O
at	O
1:100,	O
added	O
to	O
wells	O
in	O
triplicate,	O
and	O
incubated	O
for	O
1	O
hour.	O
	
Bound	O
antibody	I-KP
was	O
detected	O
by	O
the	O
addition	O
of	O
alkaline	I-KP
phosphatase-conjugated	I-KP
goat	I-KP
antihuman	I-KP
IgG	I-KP
(Kirkegaard	O
&	O
Perry	O
Laboratories,	O
Gaithersburg,	O
MD,	O
USA),	O
as	O
recommended	O
by	O
the	O
manufacturer.	O
	
A	B-KP
p-nitrophenyl	I-KP
phosphate	I-KP
substrate	I-KP
in	I-KP
diethanolamine	I-KP
buffer	O
was	O
used	O
to	O
visualize	O
bound	O
secondary	I-KP
antibody	O
when	O
the	O
reactions	O
were	O
terminated	O
at	O
30	O
minutes,	O
and	O
read	O
promptly	O
at	O
l	O
=	O
405	O
nm.	O
	
Negative	O
control	O
sera	O
(n	O
=	O
6),	O
taken	O
from	O
laboratory	O
staff	O
members	O
with	O
no	O
history	O
of	B-KP
Lyme	I-KP
disease,	O
were	O
analysed	O
on	O
each	O
plate.	O
	
A	I-KP
serum	I-KP
sample	O
was	O
considered	O
reactive	O
if	O
its	O
mean	O
absorbance	O
exceeded	O
3	O
standard	O
deviations	O
of	O
the	O
mean	O
of	O
the	O
18	O
(6	O
x	O
3)	O
negative	O
control	O
wells,	O
calculated	O
for	O
each	O
microtitre	O
plate.	O
	
Lyme	B-KP
arthritis	I-KP
was	O
originally	O
recognized	O
because	O
of	O
an	O
outbreak	O
of	O
monoarticular	B-KP
and	I-KP
oligoarticular	I-KP
arthritis	I-KP
in	O
children	O
in	O
Lyme,	O
Connecticut	O
in	O
the	O
1970s.	O
	
[1]	O
It	O
then	O
became	O
apparent	O
that	O
Lyme	B-KP
disease	I-KP
was	O
a	O
complex	O
multisystem	O
illness	O
affecting	O
primarily	O
skin,	B-KP
nervous	B-KP
system,	I-KP
heart	B-KP
or	O
joints.	B-KP
	
[2]	O
Prior	O
to	O
the	O
use	O
of	O
antibiotic	B-KP
therapy	I-KP
for	O
treatment	O
of	O
the	O
disease,	O
about	O
60%	O
of	O
untreated	O
patients	O
developed	O
Lyme	B-KP
arthritis,	I-KP
a	O
late	O
disease	O
manifestation.	O
	
[3]	O
In	O
recent	O
years,	O
over	O
30,000	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
have	O
been	O
reported	O
annually	O
to	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC),	O
and	O
in	O
a	O
third	O
of	O
reported	O
cases,	O
arthritis	B-KP
was	O
a	O
manifestation	O
of	O
the	O
disease.	O
	
[4]	O
However,	O
recent	O
CDC	O
estimates	O
suggest	O
the	O
actual	O
number	O
of	O
infections	O
with	O
the	O
Lyme	B-KP
disease	I-KP
spirochete	I-KP
may	O
be	O
10-fold	O
higher.	O
	
[5]\nThe	O
infection	O
is	O
transmitted	O
primarily	O
by	O
nymphal	B-KP
Ixodes	I-KP
scapularis	I-KP
ticks,	I-KP
which	O
quest	O
in	O
the	O
late	O
spring	O
and	O
early	O
summer.	O
	
[6]	O
However,	O
Lyme	B-KP
arthritis	I-KP
can	O
present	O
at	O
any	O
time	O
of	O
the	O
year.	O
	
The	O
majority	O
of	O
cases	O
occur	O
in	O
the	O
northeastern	O
United	O
States,	O
from	O
Maine	O
to	O
Virginia.	O
	
[5]	O
Other	O
affected	O
areas	O
in	O
the	O
U.S.	O
	
include	O
the	O
northern	O
mid-Western	O
states	O
of	O
Minnesota,	O
Wisconsin,	O
and	O
Michigan;	O
and	O
the	O
West	O
coast	O
in	O
northern	O
California.\nIn	O
the	O
United	O
States,	O
Borrelia	B-KP
burgdorferi	I-KP
is	O
the	O
sole	O
cause	O
of	O
the	O
disease,	O
but	O
subtypes	O
of	O
B.	B-KP
	
burgdorferi	I-KP
differ	O
in	O
pathogenicity.	O
	
[7,8]	O
OspC	B-KP
type	I-KP
A	I-KP
(RST1)	B-KP
strains,	O
which	O
account	O
for	O
30-50%	O
of	O
the	O
infection	O
in	O
the	O
northeastern	O
US,	O
[7,8]	O
but	O
only	O
3%	O
in	O
mid-Western	O
states,	O
[9]	O
are	O
particularly	O
virulent	O
and	O
arthritogenic.	O
	
These	O
strains	O
are	O
thought	O
to	O
have	O
played	O
an	O
important	O
role	O
in	O
the	O
emergence	O
of	O
the	O
Lyme	I-KP
disease	I-KP
epidemic	I-KP
in	O
the	O
northeastern	O
U.S.	O
	
in	O
the	O
late	O
20th	O
century.	O
	
[10]	O
Lyme	B-KP
arthritis	I-KP
was	O
originally	O
recognized	O
because	O
of	O
an	O
outbreak	O
of	O
monoarticular	B-KP
and	I-KP
oligoarticular	I-KP
arthritis	I-KP
in	O
children	O
in	O
Lyme,	O
Connecticut	O
in	O
the	O
1970s.	O
	
[1]	O
It	O
then	O
became	O
apparent	O
that	O
Lyme	B-KP
disease	I-KP
was	O
a	O
complex	O
multisystem	O
illness	O
affecting	O
primarily	O
skin,	B-KP
nervous	B-KP
system,	I-KP
heart	B-KP
or	O
joints.	B-KP
	
[2]	O
Prior	O
to	O
the	O
use	O
of	O
antibiotic	B-KP
therapy	I-KP
for	O
treatment	O
of	O
the	O
disease,	O
about	O
60%	O
of	O
untreated	O
patients	O
developed	O
Lyme	B-KP
arthritis,	I-KP
a	O
late	O
disease	O
manifestation.	O
	
[3]	O
In	O
recent	O
years,	O
over	O
30,000	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
have	O
been	O
reported	O
annually	O
to	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(CDC),	O
and	O
in	O
a	O
third	O
of	O
reported	O
cases,	O
arthritis	B-KP
was	O
a	O
manifestation	O
of	O
the	O
disease.	O
	
[4]	O
However,	O
recent	O
CDC	O
estimates	O
suggest	O
the	O
actual	O
number	O
of	O
infections	O
with	O
the	O
Lyme	B-KP
disease	I-KP
spirochete	I-KP
may	O
be	O
10-fold	O
higher.	O
	
[5]\nThe	O
infection	O
is	O
transmitted	O
primarily	O
by	O
nymphal	B-KP
Ixodes	I-KP
scapularis	I-KP
ticks,	I-KP
which	O
quest	O
in	O
the	O
late	O
spring	O
and	O
early	O
summer.	O
	
[6]	O
However,	O
Lyme	B-KP
arthritis	I-KP
can	O
present	O
at	O
any	O
time	O
of	O
the	O
year.	O
	
The	O
majority	O
of	O
cases	O
occur	O
in	O
the	O
northeastern	O
United	O
States,	O
from	O
Maine	O
to	O
Virginia.	O
	
[5]	O
Other	O
affected	O
areas	O
in	O
the	O
U.S.	O
	
include	O
the	O
northern	O
mid-Western	O
states	O
of	O
Minnesota,	O
Wisconsin,	O
and	O
Michigan;	O
and	O
the	O
West	O
coast	O
in	O
northern	O
California.\nIn	O
the	O
United	O
States,	O
Borrelia	B-KP
burgdorferi	I-KP
is	O
the	O
sole	O
cause	O
of	O
the	O
disease,	O
but	O
subtypes	O
of	O
B.	B-KP
	
burgdorferi	I-KP
differ	O
in	O
pathogenicity.	O
	
[7,8]	O
OspC	B-KP
type	I-KP
A	I-KP
(RST1)	B-KP
strains,	O
which	O
account	O
for	O
30-50%	O
of	O
the	O
infection	O
in	O
the	O
northeastern	O
US,	O
[7,8]	O
but	O
only	O
3%	O
in	O
mid-Western	O
states,	O
[9]	O
are	O
particularly	O
virulent	O
and	O
arthritogenic.	O
	
These	O
strains	O
are	O
thought	O
to	O
have	O
played	O
an	O
important	O
role	O
in	O
the	O
emergence	O
of	O
the	O
Lyme	I-KP
disease	I-KP
epidemic	I-KP
in	O
the	O
northeastern	O
U.S.	O
	
in	O
the	O
late	O
20th	O
century.	O
	
[10]	O
In	O
addition	O
to	O
serologic	B-KP
testing,	I-KP
clinical	O
features	O
may	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
other	O
arthritides.	O
	
A	O
common	O
concern	O
is	O
mechanical	O
injury	O
in	O
an	O
active	O
individual,	O
and	O
therefore,	O
orthopedists	O
are	O
often	O
the	O
first	O
specialist	O
to	O
see	O
a	O
patient	O
with	O
Lyme	B-KP
arthritis.	I-KP
	
However,	O
the	O
clinical	O
picture	O
of	O
Lyme	B-KP
arthritis	I-KP
is	O
most	O
like	O
reactive	B-KP
arthritis	I-KP
in	O
adults	O
or	O
pauciarticular	B-KP
juvenile	I-KP
idiopathic	I-KP
arthritis	I-KP
in	O
children,	O
and	O
serologic	B-KP
testing	I-KP
is	O
essential	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
these	O
entities.	O
	
Children	O
may	O
have	O
a	O
more	O
acute	O
presentation,	O
with	O
higher	O
synovial	B-KP
WBC	I-KP
counts	I-KP
which	O
may	O
suggest	O
a	O
diagnosis	O
of	O
acute	B-KP
septic	I-KP
arthritis.	I-KP
	
[22-24]	O
However,	O
Lyme	B-KP
arthritis	I-KP
typically	O
causes	O
only	O
minimal	O
pain	O
with	O
passive	O
range	O
of	O
motion,	O
and	O
involvement	O
of	O
more	O
than	O
one	O
joint	O
(currently	O
or	O
by	O
history)	O
may	O
help	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
septic	B-KP
bacterial	I-KP
arthritis.	I-KP
	
[22-24]	O
Lyme	B-KP
arthritis	I-KP
rarely,	O
if	O
ever,	O
causes	O
chronic,	O
symmetrical	B-KP
polyarthritis,	I-KP
which	O
helps	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
rheumatoid	B-KP
arthritis.	I-KP
	
Fibromyalgia	B-KP
is	O
sometimes	O
misdiagnosed	O
as	O
Lyme	B-KP
disease,	I-KP
but	O
patients	O
with	O
fibromyalgia	B-KP
generally	O
have	O
diffuse	O
pain,	O
and	O
they	O
lack	O
objective	O
evidence	O
of	O
joint	O
inflammation.\nOther	O
inflammatory	B-KP
arthritides,	I-KP
such	O
as	O
rheumatoid	B-KP
arthritis,	I-KP
reactive	B-KP
arthritis,	I-KP
or	O
psoriatic	B-KP
arthritis	I-KP
may	O
develop	O
within	O
months	O
after	O
Lyme	B-KP
disease,	I-KP
seemingly	O
triggered	O
by	O
the	O
spirochetal	B-KP
infection.	I-KP
	
Thus,	O
these	O
entities	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis.	O
	
In	O
endemic	B-KP
areas,	I-KP
concomitant	O
positive	O
serologic	O
results	O
for	O
Lyme	B-KP
disease	I-KP
in	O
patients	O
with	O
other	O
inflammatory	O
arthritides	O
can	O
present	O
a	O
diagnostic	O
challenge,	O
since	O
antibody	B-KP
responses	O
to	O
B.	B-KP
	
burgdorferi	I-KP
following	O
antibiotic-treated	B-KP
Lyme	I-KP
arthritis	I-KP
typically	O
persist	O
for	O
many	O
years.	O
	
[25]	O
In	O
addition	O
to	O
serologic	B-KP
testing,	I-KP
clinical	O
features	O
may	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
other	O
arthritides.	O
	
A	O
common	O
concern	O
is	O
mechanical	O
injury	O
in	O
an	O
active	O
individual,	O
and	O
therefore,	O
orthopedists	O
are	O
often	O
the	O
first	O
specialist	O
to	O
see	O
a	O
patient	O
with	O
Lyme	B-KP
arthritis.	I-KP
	
However,	O
the	O
clinical	O
picture	O
of	O
Lyme	B-KP
arthritis	I-KP
is	O
most	O
like	O
reactive	B-KP
arthritis	I-KP
in	O
adults	O
or	O
pauciarticular	B-KP
juvenile	I-KP
idiopathic	I-KP
arthritis	I-KP
in	O
children,	O
and	O
serologic	B-KP
testing	I-KP
is	O
essential	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
these	O
entities.	O
	
Children	O
may	O
have	O
a	O
more	O
acute	O
presentation,	O
with	O
higher	O
synovial	B-KP
WBC	I-KP
counts	I-KP
which	O
may	O
suggest	O
a	O
diagnosis	O
of	O
acute	B-KP
septic	I-KP
arthritis.	I-KP
	
[22-24]	O
However,	O
Lyme	B-KP
arthritis	I-KP
typically	O
causes	O
only	O
minimal	O
pain	O
with	O
passive	O
range	O
of	O
motion,	O
and	O
involvement	O
of	O
more	O
than	O
one	O
joint	O
(currently	O
or	O
by	O
history)	O
may	O
help	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
septic	B-KP
bacterial	I-KP
arthritis.	I-KP
	
[22-24]	O
Lyme	B-KP
arthritis	I-KP
rarely,	O
if	O
ever,	O
causes	O
chronic,	O
symmetrical	B-KP
polyarthritis,	I-KP
which	O
helps	O
to	O
distinguish	O
Lyme	B-KP
arthritis	I-KP
from	O
rheumatoid	B-KP
arthritis.	I-KP
	
Fibromyalgia	B-KP
is	O
sometimes	O
misdiagnosed	O
as	O
Lyme	B-KP
disease,	I-KP
but	O
patients	O
with	O
fibromyalgia	B-KP
generally	O
have	O
diffuse	O
pain,	O
and	O
they	O
lack	O
objective	O
evidence	O
of	O
joint	O
inflammation.\nOther	O
inflammatory	B-KP
arthritides,	I-KP
such	O
as	O
rheumatoid	B-KP
arthritis,	I-KP
reactive	B-KP
arthritis,	I-KP
or	O
psoriatic	B-KP
arthritis	I-KP
may	O
develop	O
within	O
months	O
after	O
Lyme	B-KP
disease,	I-KP
seemingly	O
triggered	O
by	O
the	O
spirochetal	B-KP
infection.	I-KP
	
Thus,	O
these	O
entities	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis.	O
	
In	O
endemic	B-KP
areas,	I-KP
concomitant	O
positive	O
serologic	O
results	O
for	O
Lyme	B-KP
disease	I-KP
in	O
patients	O
with	O
other	O
inflammatory	O
arthritides	O
can	O
present	O
a	O
diagnostic	O
challenge,	O
since	O
antibody	B-KP
responses	O
to	O
B.	B-KP
	
burgdorferi	I-KP
following	O
antibiotic-treated	B-KP
Lyme	I-KP
arthritis	I-KP
typically	O
persist	O
for	O
many	O
years.	O
	
[25]	O
In	O
our	O
experience,	O
some	O
patients	O
do	O
require	O
longer	O
courses	O
of	O
antibiotic	B-KP
therapy	I-KP
for	O
effective	O
treatment	O
of	O
Lyme	B-KP
arthritis.	I-KP
	
[12]	O
Thus,	O
if	O
there	O
is	O
mild	O
residual	O
joint	O
swelling	O
after	O
a	O
30-day	O
course	O
of	O
oral	B-KP
antibiotics,	I-KP
we	O
repeat	O
the	O
oral	B-KP
antibiotic	I-KP
regimen	O
for	O
another	O
30	O
days.	O
	
However,	O
for	O
patients	O
who	O
continue	O
to	O
have	O
moderate-to-severe	O
joint	O
swelling	O
after	O
a	O
30-day	O
course	O
of	O
oral	B-KP
antibiotics,	I-KP
we	O
treat	O
with	O
IV	B-KP
ceftriaxone,	I-KP
2gm/day.	O
	
Although	O
there	O
is	O
trend	O
toward	O
greater	O
efficacy	O
with	O
4	O
weeks	O
compared	O
with	O
2	O
weeks	O
of	O
antibiotics,	B-KP
there	O
is	O
also	O
a	O
greater	O
frequency	O
of	O
adverse	O
events.38	O
Thus,	O
our	O
practice	O
is	O
to	O
prescribe	O
a	O
4-week	O
course	O
of	O
IV	B-KP
therapy,	I-KP
but	O
to	O
monitor	O
the	O
patient	O
closely	O
and	O
to	O
stop	O
the	O
antibiotic	B-KP
if	O
complications	O
occur.\nEven	O
in	O
patients	O
who	O
had	O
minimal	O
or	O
no	O
improvement	O
with	O
oral	B-KP
doxycycline,	I-KP
we	O
typically	O
observe	O
moderate	O
improvement	O
or	O
even	O
complete	O
resolution	O
of	O
arthritis	O
with	O
IV	B-KP
therapy.	I-KP
	
Moreover,	O
even	O
in	O
those	O
with	O
persistent	B-KP
joint	I-KP
inflammation,	I-KP
the	O
synovitis	B-KP
tends	O
to	O
change	O
after	O
IV	B-KP
therapy	I-KP
with	O
decreased	O
size	O
of	O
effusions	O
but	O
continued	O
synovial	B-KP
tissue	I-KP
hypertrophy	I-KP
and	O
inflammation.	O
	
Courses	O
of	O
longer	O
than	O
30	O
days	O
of	O
IV	B-KP
antibiotics	I-KP
seem	O
not	O
to	O
be	O
beneficial	O
and	O
may	O
be	O
associated	O
with	O
a	O
still	O
greater	O
frequency	O
of	O
adverse	O
effect.	O
	
[39]	O
Additionally,	O
a	O
recent	O
double-blind,	O
randomized,	O
placebo-controlled	O
study	O
of	O
patients	O
in	O
Europe	O
did	O
not	O
find	O
a	O
benefit	O
of	O
additional	O
oral	B-KP
amoxicillin	I-KP
therapy	I-KP
following	O
treatment	O
with	O
IV	B-KP
ceftriaxone.	I-KP
	
[40]	O
A	O
number	O
of	O
newer	O
oral	O
antibiotics	B-KP
in	O
an	O
FDA	O
approved	O
drug	O
library,	O
including	O
daptomycin,	B-KP
carbomycin,	B-KP
and	O
cefoperazone,	B-KP
have	O
been	O
shown	O
to	O
have	O
marked	O
efficacy	O
against	O
persisting	O
spirochetes	B-KP
in	O
culture,	O
[41]	O
but	O
it	O
is	O
not	O
yet	O
known	O
whether	O
such	O
antibiotics	B-KP
would	O
be	O
effective	O
in	O
patients	O
with	O
Lyme	B-KP
arthritis	I-KP
that	O
is	O
more	O
difficult	O
to	O
treat.	O
	
In	O
our	O
experience,	O
some	O
patients	O
do	O
require	O
longer	O
courses	O
of	O
antibiotic	B-KP
therapy	I-KP
for	O
effective	O
treatment	O
of	O
Lyme	B-KP
arthritis.	I-KP
	
[12]	O
Thus,	O
if	O
there	O
is	O
mild	O
residual	O
joint	O
swelling	O
after	O
a	O
30-day	O
course	O
of	O
oral	B-KP
antibiotics,	I-KP
we	O
repeat	O
the	O
oral	B-KP
antibiotic	I-KP
regimen	O
for	O
another	O
30	O
days.	O
	
However,	O
for	O
patients	O
who	O
continue	O
to	O
have	O
moderate-to-severe	O
joint	O
swelling	O
after	O
a	O
30-day	O
course	O
of	O
oral	B-KP
antibiotics,	I-KP
we	O
treat	O
with	O
IV	B-KP
ceftriaxone,	I-KP
2gm/day.	O
	
Although	O
there	O
is	O
trend	O
toward	O
greater	O
efficacy	O
with	O
4	O
weeks	O
compared	O
with	O
2	O
weeks	O
of	O
antibiotics,	B-KP
there	O
is	O
also	O
a	O
greater	O
frequency	O
of	O
adverse	O
events.38	O
Thus,	O
our	O
practice	O
is	O
to	O
prescribe	O
a	O
4-week	O
course	O
of	O
IV	B-KP
therapy,	I-KP
but	O
to	O
monitor	O
the	O
patient	O
closely	O
and	O
to	O
stop	O
the	O
antibiotic	B-KP
if	O
complications	O
occur.\nEven	O
in	O
patients	O
who	O
had	O
minimal	O
or	O
no	O
improvement	O
with	O
oral	B-KP
doxycycline,	I-KP
we	O
typically	O
observe	O
moderate	O
improvement	O
or	O
even	O
complete	O
resolution	O
of	O
arthritis	O
with	O
IV	B-KP
therapy.	I-KP
	
Moreover,	O
even	O
in	O
those	O
with	O
persistent	B-KP
joint	I-KP
inflammation,	I-KP
the	O
synovitis	B-KP
tends	O
to	O
change	O
after	O
IV	B-KP
therapy	I-KP
with	O
decreased	O
size	O
of	O
effusions	O
but	O
continued	O
synovial	B-KP
tissue	I-KP
hypertrophy	I-KP
and	O
inflammation.	O
	
Courses	O
of	O
longer	O
than	O
30	O
days	O
of	O
IV	B-KP
antibiotics	I-KP
seem	O
not	O
to	O
be	O
beneficial	O
and	O
may	O
be	O
associated	O
with	O
a	O
still	O
greater	O
frequency	O
of	O
adverse	O
effect.	O
	
[39]	O
Additionally,	O
a	O
recent	O
double-blind,	O
randomized,	O
placebo-controlled	O
study	O
of	O
patients	O
in	O
Europe	O
did	O
not	O
find	O
a	O
benefit	O
of	O
additional	O
oral	B-KP
amoxicillin	I-KP
therapy	I-KP
following	O
treatment	O
with	O
IV	B-KP
ceftriaxone.	I-KP
	
[40]	O
A	O
number	O
of	O
newer	O
oral	O
antibiotics	B-KP
in	O
an	O
FDA	O
approved	O
drug	O
library,	O
including	O
daptomycin,	B-KP
carbomycin,	B-KP
and	O
cefoperazone,	B-KP
have	O
been	O
shown	O
to	O
have	O
marked	O
efficacy	O
against	O
persisting	O
spirochetes	B-KP
in	O
culture,	O
[41]	O
but	O
it	O
is	O
not	O
yet	O
known	O
whether	O
such	O
antibiotics	B-KP
would	O
be	O
effective	O
in	O
patients	O
with	O
Lyme	B-KP
arthritis	I-KP
that	O
is	O
more	O
difficult	O
to	O
treat.	O
	
Arthritis	O
is	O
a	O
late	B-KP
manifestation	I-KP
of	I-KP
Lyme	I-KP
disease,	I-KP
usually	O
beginning	O
months	O
after	O
the	O
tick	O
bite.	O
	
However,	O
a	O
history	O
of	O
erythema	B-KP
migrans	I-KP
or	O
tick	O
bite	O
may	O
be	O
lacking.	O
	
Patients	O
have	O
intermittent	O
or	O
persistent	O
attacks	O
of	O
joint	O
swelling	O
and	O
pain,	O
primarily	O
in	O
one	O
or	O
a	O
few	O
large	O
joints,	O
often	O
the	O
knee,	O
during	O
a	O
period	O
of	O
months	O
to	O
several	O
years,	O
with	O
few	O
systemic	O
manifestations.	O
	
The	O
diagnosis	O
is	O
established	O
by	O
two-tier	B-KP
serologic	I-KP
testing	I-KP
for	O
B.	B-KP
	
burgdorferi	I-KP
by	O
ELISA	B-KP
and	O
IgG	B-KP
Western	I-KP
blotting,	I-KP
which	O
typically	O
shows	O
strong	O
responses	O
to	O
many	O
spirochetal	B-KP
proteins	I-KP
with	O
many	O
bands	O
present.	O
	
PCR	B-KP
testing	I-KP
of	O
synovial	O
fluid	O
for	O
B.	B-KP
	
burgdorferi	I-KP
DNA	I-KP
is	O
often	O
positive	O
prior	O
to	O
antibiotic	B-KP
therapy,	I-KP
but	O
the	O
test	O
is	O
not	O
a	O
reliable	O
indicator	O
of	O
spirochetal	B-KP
eradication	I-KP
following	I-KP
antibiotic	I-KP
treatment,	I-KP
since	O
spirochetal	B-KP
DNA	I-KP
may	O
persist	O
after	O
spirochetal	O
killing.	O
	
Initial	O
recommended	O
therapies	O
include	O
a	O
30-day	O
course	O
of	O
oral	B-KP
doxycycline	I-KP
or	O
amoxicillin.	B-KP
	
However,	O
for	O
patients	O
with	O
persistent	O
joint	O
swelling	O
despite	O
oral	B-KP
therapy,	I-KP
IV	B-KP
ceftriaxone	I-KP
for	O
2	O
to	O
4	O
weeks	O
may	O
be	O
needed	O
for	O
successful	O
treatment.	O
	
A	O
small	O
percentage	O
of	O
patients	O
may	O
have	O
persistent	O
arthritis	O
for	O
months	O
or	O
several	O
years	O
after	O
both	O
oral	B-KP
and	I-KP
IV	I-KP
antibiotic	I-KP
therapy,	I-KP
which	O
may	O
be	O
treated	O
successfully	O
with	O
anti-inflammatory	B-KP
agents,	I-KP
DMARDs,	B-KP
or	O
synovectomy.	B-KP
	
The	O
antibody	B-KP
response	O
to	O
B.	B-KP
	
burgdorferi	I-KP
declines	O
slowly	O
after	O
treatment,	O
but	O
the	O
test	O
typically	O
remains	O
positive	O
for	O
years	O
after	O
therapy.	O
	
Arthritis	O
is	O
a	O
late	B-KP
manifestation	I-KP
of	I-KP
Lyme	I-KP
disease,	I-KP
usually	O
beginning	O
months	O
after	O
the	O
tick	O
bite.	O
	
However,	O
a	O
history	O
of	O
erythema	B-KP
migrans	I-KP
or	O
tick	O
bite	O
may	O
be	O
lacking.	O
	
Patients	O
have	O
intermittent	O
or	O
persistent	O
attacks	O
of	O
joint	O
swelling	O
and	O
pain,	O
primarily	O
in	O
one	O
or	O
a	O
few	O
large	O
joints,	O
often	O
the	O
knee,	O
during	O
a	O
period	O
of	O
months	O
to	O
several	O
years,	O
with	O
few	O
systemic	O
manifestations.	O
	
The	O
diagnosis	O
is	O
established	O
by	O
two-tier	B-KP
serologic	I-KP
testing	I-KP
for	O
B.	B-KP
	
burgdorferi	I-KP
by	O
ELISA	B-KP
and	O
IgG	B-KP
Western	I-KP
blotting,	I-KP
which	O
typically	O
shows	O
strong	O
responses	O
to	O
many	O
spirochetal	B-KP
proteins	I-KP
with	O
many	O
bands	O
present.	O
	
PCR	B-KP
testing	I-KP
of	O
synovial	O
fluid	O
for	O
B.	B-KP
	
burgdorferi	I-KP
DNA	I-KP
is	O
often	O
positive	O
prior	O
to	O
antibiotic	B-KP
therapy,	I-KP
but	O
the	O
test	O
is	O
not	O
a	O
reliable	O
indicator	O
of	O
spirochetal	B-KP
eradication	I-KP
following	I-KP
antibiotic	I-KP
treatment,	I-KP
since	O
spirochetal	B-KP
DNA	I-KP
may	O
persist	O
after	O
spirochetal	O
killing.	O
	
Initial	O
recommended	O
therapies	O
include	O
a	O
30-day	O
course	O
of	O
oral	B-KP
doxycycline	I-KP
or	O
amoxicillin.	B-KP
	
However,	O
for	O
patients	O
with	O
persistent	O
joint	O
swelling	O
despite	O
oral	B-KP
therapy,	I-KP
IV	B-KP
ceftriaxone	I-KP
for	O
2	O
to	O
4	O
weeks	O
may	O
be	O
needed	O
for	O
successful	O
treatment.	O
	
A	O
small	O
percentage	O
of	O
patients	O
may	O
have	O
persistent	O
arthritis	O
for	O
months	O
or	O
several	O
years	O
after	O
both	O
oral	B-KP
and	I-KP
IV	I-KP
antibiotic	I-KP
therapy,	I-KP
which	O
may	O
be	O
treated	O
successfully	O
with	O
anti-inflammatory	B-KP
agents,	I-KP
DMARDs,	B-KP
or	O
synovectomy.	B-KP
	
The	O
antibody	B-KP
response	O
to	O
B.	B-KP
	
burgdorferi	I-KP
declines	O
slowly	O
after	O
treatment,	O
but	O
the	O
test	O
typically	O
remains	O
positive	O
for	O
years	O
after	O
therapy.	O
	
Patients	O
were	O
classified	O
as	O
having	O
LM	B-KP
if	O
they	O
met	O
the	O
criteria	O
established	O
by	O
the	O
CDC	O
for	O
Lyme	B-KP
disease	I-KP
(positive	O
serology	O
with	O
Western	O
blot	O
confirmation	O
or	O
erythema	B-KP
migrans	I-KP
observed	O
by	O
a	O
physician)	O
and	O
had	O
meningitis.	O
	
[1]	O
Criteria	O
for	O
serologic	B-KP
diagnosis	I-KP
were	O
based	O
on	O
published	O
criteria	O
for	O
results	O
from	O
commercial	O
laboratories	O
[8]	O
and	O
our	O
hospital’s	O
laboratory.	O
	
[9]	O
If	O
initial	O
Lyme-serology	B-KP
results	I-KP
were	O
equivocal	O
but	O
follow-up	O
testing	O
was	O
positive,	O
these	O
children	O
were	O
considered	O
to	O
have	O
Lyme	B-KP
disease.	I-KP
	
Patients	O
with	O
meningitis	O
who	O
did	O
not	O
meet	O
CDC	O
criteria	O
for	O
Lyme	B-KP
disease	I-KP
were	O
classified	O
as	O
having	O
AM.	B-KP
	
The	O
final	O
discharge	O
diagnosis	O
of	O
all	O
patients	O
was	O
extracted	O
from	O
the	O
medical	O
chart.\nLaboratory	O
values	O
(Lyme	B-KP
serology,	O
CSF	I-KP
red	I-KP
blood	I-KP
cell	I-KP
count,	O
CSF	I-KP
WBC,	O
CSF	I-KP
WBC	I-KP
differential,	O
CSF	I-KP
bacterial	I-KP
culture,	O
CSF	I-KP
viral	I-KP
culture,	O
and	O
CSF	I-KP
enterovirus	I-KP
PCR)	O
and	O
demographic	O
information	O
(age,	O
gender,	O
race,	O
and	O
month	O
of	O
presentation)	O
were	O
abstracted	O
electronically	O
from	O
our	O
hospital’s	O
laboratory	O
database.	O
	
Lyme	I-KP
serology	I-KP
was	O
completed	O
by	O
our	O
hospital	O
laboratory	O
using	O
a	O
previously	O
described	O
protocol.9	O
Standard	O
techniques	O
were	O
used	O
for	O
CSF	I-KP
bacterial	I-KP
and	I-KP
viral	I-KP
cultures.	O
	
The	O
virology	O
laboratory	O
of	O
the	O
Children’s	O
Hospital	O
of	O
Philadelphia	O
(Philadelphia,	O
PA)	O
performed	O
all	O
enterovirus	I-KP
CSF	I-KP
PCR	I-KP
testing.	O
	
Patients	O
were	O
classified	O
as	O
having	O
LM	B-KP
if	O
they	O
met	O
the	O
criteria	O
established	O
by	O
the	O
CDC	O
for	O
Lyme	B-KP
disease	I-KP
(positive	O
serology	O
with	O
Western	O
blot	O
confirmation	O
or	O
erythema	B-KP
migrans	I-KP
observed	O
by	O
a	O
physician)	O
and	O
had	O
meningitis.	O
	
[1]	O
Criteria	O
for	O
serologic	B-KP
diagnosis	I-KP
were	O
based	O
on	O
published	O
criteria	O
for	O
results	O
from	O
commercial	O
laboratories	O
[8]	O
and	O
our	O
hospital’s	O
laboratory.	O
	
[9]	O
If	O
initial	O
Lyme-serology	B-KP
results	I-KP
were	O
equivocal	O
but	O
follow-up	O
testing	O
was	O
positive,	O
these	O
children	O
were	O
considered	O
to	O
have	O
Lyme	B-KP
disease.	I-KP
	
Patients	O
with	O
meningitis	O
who	O
did	O
not	O
meet	O
CDC	O
criteria	O
for	O
Lyme	B-KP
disease	I-KP
were	O
classified	O
as	O
having	O
AM.	B-KP
	
The	O
final	O
discharge	O
diagnosis	O
of	O
all	O
patients	O
was	O
extracted	O
from	O
the	O
medical	O
chart.\nLaboratory	O
values	O
(Lyme	B-KP
serology,	O
CSF	I-KP
red	I-KP
blood	I-KP
cell	I-KP
count,	O
CSF	I-KP
WBC,	O
CSF	I-KP
WBC	I-KP
differential,	O
CSF	I-KP
bacterial	I-KP
culture,	O
CSF	I-KP
viral	I-KP
culture,	O
and	O
CSF	I-KP
enterovirus	I-KP
PCR)	O
and	O
demographic	O
information	O
(age,	O
gender,	O
race,	O
and	O
month	O
of	O
presentation)	O
were	O
abstracted	O
electronically	O
from	O
our	O
hospital’s	O
laboratory	O
database.	O
	
Lyme	I-KP
serology	I-KP
was	O
completed	O
by	O
our	O
hospital	O
laboratory	O
using	O
a	O
previously	O
described	O
protocol.9	O
Standard	O
techniques	O
were	O
used	O
for	O
CSF	I-KP
bacterial	I-KP
and	I-KP
viral	I-KP
cultures.	O
	
The	O
virology	O
laboratory	O
of	O
the	O
Children’s	O
Hospital	O
of	O
Philadelphia	O
(Philadelphia,	O
PA)	O
performed	O
all	O
enterovirus	I-KP
CSF	I-KP
PCR	I-KP
testing.	O
	
Neuroimaging	B-KP
findings	O
are	O
typically	O
unremarkable	O
in	O
Lyme	B-KP
disease.	I-KP
	
Single-photon	B-KP
emission	I-KP
computed	I-KP
tomography	I-KP
scans	I-KP
are	O
more	O
likely	O
to	O
show	O
abnormalities	O
(often	O
with	O
multifocal	O
areas	O
of	O
decreased	O
perfusion	O
in	O
the	O
cortex	B-KP
and	O
subcortical	B-KP
white	I-KP
matter)	I-KP
than	O
magnetic	B-KP
resonance	I-KP
imaging	I-KP
scans	I-KP
are,	O
but	O
single-photon	B-KP
emission	I-KP
computed	I-KP
tomography	I-KP
scans	I-KP
offer	O
little	O
positive	O
or	O
negative	O
predictive	O
value	O
in	O
the	O
diagnosis.	O
	
[18–20]	O
MRT	O
2-weighted	O
imaging	O
in	O
some	O
cases	O
can	O
reveal	O
white	B-KP
matter	I-KP
lesions,	I-KP
enlarged	B-KP
ventricles,	I-KP
and	O
cortical	B-KP
atrophy;	I-KP
however,	O
these	O
results	O
are	O
nonspecific,	O
and	O
the	O
spirochete	B-KP
does	O
not	O
appear	O
to	O
preferentially	O
settle	O
in	O
certain	O
brain	B-KP
territories	I-KP
(as	O
it	O
does	O
in	O
herpes	O
simplex	O
virus	O
infection).	O
	
Neuropsychologic	B-KP
testing	I-KP
sometimes	O
confirms	O
objective	O
(often	O
nonspecific)	O
impairments,	O
as	O
is	O
the	O
case	O
with	O
other	O
infectious	O
diseases.	O
	
[19,21]	O
Electroencephalograms	B-KP
typically	O
lack	O
abnormal	O
findings,	O
except	O
in	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
that	O
present	O
with	O
encephalitis.	B-KP
	
Cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
analysis	O
for	O
Lyme	I-KP
antibodies	I-KP
is	O
not	O
necessary	O
for	O
the	O
diagnosis	O
of	O
Lyme	I-KP
disease	I-KP
even	O
when	O
the	O
nervous	I-KP
system	I-KP
is	O
affected.	O
	
[22]	O
However,it	O
can	O
be	O
helpful	O
to	O
exclude	O
other,	O
more	O
dangerous,	O
pathogens.	O
	
It	O
is	O
rare	O
to	O
have	O
CSF	I-KP
antibodies	I-KP
without	O
serologic	O
ones,	O
so	O
the	O
absence	O
of	O
serologic	I-KP
antibodies	I-KP
indicates	O
that	O
Lyme	I-KP
disease	I-KP
is	O
not	O
present.	O
	
Likewise,	O
a	O
negative	O
result	O
on	O
CSF	I-KP
antibody	I-KP
test	I-KP
does	O
not	O
exclude	O
central	I-KP
nervous	I-KP
system	I-KP
Lyme	I-KP
disease	I-KP
and	O
a	O
positive	O
CSF	I-KP
antibody	I-KP
test	I-KP
does	O
not	O
establish	O
the	O
presence	O
of	O
Lyme	I-KP
disease	I-KP
(as	O
antibodies	O
can	O
diffuse	O
from	O
the	O
serum	O
to	O
the	O
CSF).	O
	
Neuroimaging	B-KP
findings	O
are	O
typically	O
unremarkable	O
in	O
Lyme	B-KP
disease.	I-KP
	
Single-photon	B-KP
emission	I-KP
computed	I-KP
tomography	I-KP
scans	I-KP
are	O
more	O
likely	O
to	O
show	O
abnormalities	O
(often	O
with	O
multifocal	O
areas	O
of	O
decreased	O
perfusion	O
in	O
the	O
cortex	B-KP
and	O
subcortical	B-KP
white	I-KP
matter)	I-KP
than	O
magnetic	B-KP
resonance	I-KP
imaging	I-KP
scans	I-KP
are,	O
but	O
single-photon	B-KP
emission	I-KP
computed	I-KP
tomography	I-KP
scans	I-KP
offer	O
little	O
positive	O
or	O
negative	O
predictive	O
value	O
in	O
the	O
diagnosis.	O
	
[18–20]	O
MRT	O
2-weighted	O
imaging	O
in	O
some	O
cases	O
can	O
reveal	O
white	B-KP
matter	I-KP
lesions,	I-KP
enlarged	B-KP
ventricles,	I-KP
and	O
cortical	B-KP
atrophy;	I-KP
however,	O
these	O
results	O
are	O
nonspecific,	O
and	O
the	O
spirochete	B-KP
does	O
not	O
appear	O
to	O
preferentially	O
settle	O
in	O
certain	O
brain	B-KP
territories	I-KP
(as	O
it	O
does	O
in	O
herpes	O
simplex	O
virus	O
infection).	O
	
Neuropsychologic	B-KP
testing	I-KP
sometimes	O
confirms	O
objective	O
(often	O
nonspecific)	O
impairments,	O
as	O
is	O
the	O
case	O
with	O
other	O
infectious	O
diseases.	O
	
[19,21]	O
Electroencephalograms	B-KP
typically	O
lack	O
abnormal	O
findings,	O
except	O
in	O
cases	O
of	O
Lyme	B-KP
disease	I-KP
that	O
present	O
with	O
encephalitis.	B-KP
	
Cerebrospinal	B-KP
fluid	I-KP
(CSF)	B-KP
analysis	O
for	O
Lyme	I-KP
antibodies	I-KP
is	O
not	O
necessary	O
for	O
the	O
diagnosis	O
of	O
Lyme	I-KP
disease	I-KP
even	O
when	O
the	O
nervous	I-KP
system	I-KP
is	O
affected.	O
	
[22]	O
However,it	O
can	O
be	O
helpful	O
to	O
exclude	O
other,	O
more	O
dangerous,	O
pathogens.	O
	
It	O
is	O
rare	O
to	O
have	O
CSF	I-KP
antibodies	I-KP
without	O
serologic	O
ones,	O
so	O
the	O
absence	O
of	O
serologic	I-KP
antibodies	I-KP
indicates	O
that	O
Lyme	I-KP
disease	I-KP
is	O
not	O
present.	O
	
Likewise,	O
a	O
negative	O
result	O
on	O
CSF	I-KP
antibody	I-KP
test	I-KP
does	O
not	O
exclude	O
central	I-KP
nervous	I-KP
system	I-KP
Lyme	I-KP
disease	I-KP
and	O
a	O
positive	O
CSF	I-KP
antibody	I-KP
test	I-KP
does	O
not	O
establish	O
the	O
presence	O
of	O
Lyme	I-KP
disease	I-KP
(as	O
antibodies	O
can	O
diffuse	O
from	O
the	O
serum	O
to	O
the	O
CSF).	O
	
In	O
contrast	O
to	O
post-treatment	O
Lyme	B-KP
disease	I-KP
syndrome,	I-KP
chronic	O
Lyme	B-KP
disease	I-KP
is	O
a	O
controversial	O
term	O
that	O
causes	O
considerable	O
confusion	O
owing	O
to	O
lack	O
of	O
a	O
standardized	O
case	O
definition,	O
with	O
some	O
even	O
questioning	O
its	O
existence.	O
	
Ingeneral,	O
it	O
refers	O
to	O
individuals	O
who	O
attribute	O
bodily	O
symptoms	O
to	O
a	O
persistent	B-KP
Lyme	I-KP
infection,irrespective	O
of	O
whether	O
theyhave	O
a	O
history	O
of	O
Lyme	B-KP
disease.	I-KP
	
Multiple	O
patient	O
advocacy	O
groups	O
that	O
have	O
encouraged	O
patients	O
(many	O
of	O
whom	O
had	O
negative	O
results	O
on	O
serologic	B-KP
testing)	I-KP
to	O
think	O
that	O
they	O
have	O
chronic	O
infections	O
have	O
flourished.	O
	
[32]	O
This	O
may	O
prevent	O
some	O
individuals	O
from	O
seeking	O
a	O
second	O
opinion	O
that	O
may	O
reveal	O
another	O
disorder.	O
	
Some	O
groups	O
have	O
created	O
their	O
own	O
guide	O
lines	O
for	O
the	O
management	O
of	O
chronic	O
Lyme	B-KP
disease.	I-KP
	
Others	O
contend	O
that	O
physicians	O
lack	O
sufficient	O
knowledge	O
about	O
Lyme	B-KP
disease	I-KP
(and	O
are	O
underdiagnosing	O
it)	O
and	O
that	O
assays	O
used	O
to	O
make	O
the	O
diagnosis	O
are	O
not	O
credible.	O
	
In	O
contrast	O
to	O
post-treatment	O
Lyme	B-KP
disease	I-KP
syndrome,	I-KP
chronic	O
Lyme	B-KP
disease	I-KP
is	O
a	O
controversial	O
term	O
that	O
causes	O
considerable	O
confusion	O
owing	O
to	O
lack	O
of	O
a	O
standardized	O
case	O
definition,	O
with	O
some	O
even	O
questioning	O
its	O
existence.	O
	
Ingeneral,	O
it	O
refers	O
to	O
individuals	O
who	O
attribute	O
bodily	O
symptoms	O
to	O
a	O
persistent	B-KP
Lyme	I-KP
infection,irrespective	O
of	O
whether	O
theyhave	O
a	O
history	O
of	O
Lyme	B-KP
disease.	I-KP
	
Multiple	O
patient	O
advocacy	O
groups	O
that	O
have	O
encouraged	O
patients	O
(many	O
of	O
whom	O
had	O
negative	O
results	O
on	O
serologic	B-KP
testing)	I-KP
to	O
think	O
that	O
they	O
have	O
chronic	O
infections	O
have	O
flourished.	O
	
[32]	O
This	O
may	O
prevent	O
some	O
individuals	O
from	O
seeking	O
a	O
second	O
opinion	O
that	O
may	O
reveal	O
another	O
disorder.	O
	
Some	O
groups	O
have	O
created	O
their	O
own	O
guide	O
lines	O
for	O
the	O
management	O
of	O
chronic	O
Lyme	B-KP
disease.	I-KP
	
Others	O
contend	O
that	O
physicians	O
lack	O
sufficient	O
knowledge	O
about	O
Lyme	B-KP
disease	I-KP
(and	O
are	O
underdiagnosing	O
it)	O
and	O
that	O
assays	O
used	O
to	O
make	O
the	O
diagnosis	O
are	O
not	O
credible.	O
	
The	O
majority	O
of	O
infections	O
can	O
be	O
cured	O
with	O
use	O
of	O
recommended	O
antimicrobials.	B-KP
	
Patients	O
with	O
physician-diagnosed	O
EMcan	B-KP
be	O
treated	O
with	O
oral	B-KP
doxycycline,	I-KP
amoxicillin,	B-KP
or	O
cefuroxime	B-KP
axetil	I-KP
(7,8).	O
	
Patients	O
with	O
other	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
are	O
treated	O
with	O
either	O
oral	B-KP
or	I-KP
intravenous	I-KP
antimicrobials	I-KP
(e.g.,	O
ceftriaxone),	O
depending	O
on	O
the	O
specific	O
clinical	O
condition.\nMeasures	O
to	O
prevent	O
Lyme	B-KP
disease	I-KP
and	O
other	O
tickborne	O
infections	O
include	O
avoiding	O
tick-infested	O
areas	O
when	O
possible,	O
using	O
insect	O
repellents	O
containing	O
20%–30%	O
DEET	O
(N,N-diethyl-m-toluamide)	O
on	O
exposed	O
skin	B-KP
and	O
clothing,	O
and	O
performing	O
daily	O
self-examination	O
for	O
ticks	O
(13).	O
	
Tick	O
abundance	O
can	O
be	O
reduced	O
around	O
private	O
homes	O
and	O
in	O
recreational	O
areas	O
by	O
removing	O
brush	O
and	O
leaf	O
litter,	O
creating	O
a	O
buffer	O
zone	O
of	O
wood	O
chips	O
or	O
gravel	O
between	O
forests	O
and	O
lawn,	O
applying	O
acaricides,	O
and	O
excluding	O
deer	O
(13,14).	O
	
Tickborne	O
illness	O
can	O
be	O
mitigated	O
by	O
prompt	O
and	O
proper	O
tick	O
removal	O
and	O
by	O
recognizing	O
and	O
seeking	O
treatment	O
for	O
early	O
signs	O
of	O
illness	O
(8,15,16).	O
	
A	O
single	O
dose	O
of	O
doxycycline	B-KP
should	O
be	O
considered	O
for	O
prophylaxis	O
of	O
Lyme	B-KP
disease	I-KP
in	O
persons	O
aged	O
>8	O
years	O
who	O
have	O
been	O
bitten	O
by	O
a	O
nymph	O
or	O
adult	O
I.	B-KP
	
scapularis	I-KP
or	O
I.	B-KP
	
pacificus	I-KP
tick	I-KP
in	O
an	O
area	O
in	O
which	O
at	O
least	O
20%	O
of	O
ticks	O
are	O
thought	O
to	O
be	O
infected	O
with	O
B.	B-KP
	
burgdorferi	I-KP
(8).	O
	
The	O
tick	O
must	O
have	O
been	O
attached	O
for	O
≥36	O
hours	O
and	O
prophylactic	B-KP
antibiotic	I-KP
administered	O
within	O
72	O
hours	O
of	O
tick	O
removal	O
(8).	O
	
The	O
majority	O
of	O
infections	O
can	O
be	O
cured	O
with	O
use	O
of	O
recommended	O
antimicrobials.	B-KP
	
Patients	O
with	O
physician-diagnosed	O
EMcan	B-KP
be	O
treated	O
with	O
oral	B-KP
doxycycline,	I-KP
amoxicillin,	B-KP
or	O
cefuroxime	B-KP
axetil	I-KP
(7,8).	O
	
Patients	O
with	O
other	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
are	O
treated	O
with	O
either	O
oral	B-KP
or	I-KP
intravenous	I-KP
antimicrobials	I-KP
(e.g.,	O
ceftriaxone),	O
depending	O
on	O
the	O
specific	O
clinical	O
condition.\nMeasures	O
to	O
prevent	O
Lyme	B-KP
disease	I-KP
and	O
other	O
tickborne	O
infections	O
include	O
avoiding	O
tick-infested	O
areas	O
when	O
possible,	O
using	O
insect	O
repellents	O
containing	O
20%–30%	O
DEET	O
(N,N-diethyl-m-toluamide)	O
on	O
exposed	O
skin	B-KP
and	O
clothing,	O
and	O
performing	O
daily	O
self-examination	O
for	O
ticks	O
(13).	O
	
Tick	O
abundance	O
can	O
be	O
reduced	O
around	O
private	O
homes	O
and	O
in	O
recreational	O
areas	O
by	O
removing	O
brush	O
and	O
leaf	O
litter,	O
creating	O
a	O
buffer	O
zone	O
of	O
wood	O
chips	O
or	O
gravel	O
between	O
forests	O
and	O
lawn,	O
applying	O
acaricides,	O
and	O
excluding	O
deer	O
(13,14).	O
	
Tickborne	O
illness	O
can	O
be	O
mitigated	O
by	O
prompt	O
and	O
proper	O
tick	O
removal	O
and	O
by	O
recognizing	O
and	O
seeking	O
treatment	O
for	O
early	O
signs	O
of	O
illness	O
(8,15,16).	O
	
A	O
single	O
dose	O
of	O
doxycycline	B-KP
should	O
be	O
considered	O
for	O
prophylaxis	O
of	O
Lyme	B-KP
disease	I-KP
in	O
persons	O
aged	O
>8	O
years	O
who	O
have	O
been	O
bitten	O
by	O
a	O
nymph	O
or	O
adult	O
I.	B-KP
	
scapularis	I-KP
or	O
I.	B-KP
	
pacificus	I-KP
tick	I-KP
in	O
an	O
area	O
in	O
which	O
at	O
least	O
20%	O
of	O
ticks	O
are	O
thought	O
to	O
be	O
infected	O
with	O
B.	B-KP
	
burgdorferi	I-KP
(8).	O
	
The	O
tick	O
must	O
have	O
been	O
attached	O
for	O
≥36	O
hours	O
and	O
prophylactic	B-KP
antibiotic	I-KP
administered	O
within	O
72	O
hours	O
of	O
tick	O
removal	O
(8).	O
	
To	O
reduce	O
the	O
risk	O
of	O
tick	O
bites	O
while	O
in	O
the	O
field,	O
the	O
current	O
Department	O
of	O
Defense	O
(DoD)	O
repellent	B-KP
system	I-KP
was	O
adopted	O
in	O
1991.9	O
This	O
system	O
provides	O
specific	O
personal	B-KP
protective	I-KP
measure	I-KP
(PPM)	B-KP
guidelines	O
for	O
use	O
with	O
the	O
military	O
field	O
uniform,	O
which	O
provides	O
barrier	O
and	O
chemical	O
protection	O
against	O
arthropod	I-KP
borne	I-KP
infections.	O
	
However,	O
compliance	O
with	O
these	O
guidelines	O
has	O
been	O
demonstrated	O
to	O
be	O
inadequate,	O
even	O
under	O
conditions	O
of	O
high	O
risk	O
for	O
arthropod-related	I-KP
disease	I-KP
transmission	O
and	O
nuisance	O
bites.	O
	
Although	O
medical	O
threat	O
briefings	O
are	O
commonly	O
given	O
prior	O
to	O
field	O
missions,	O
studies	O
suggest	O
not	O
only	O
that	O
military	O
personnel	O
have	O
poor	O
knowledge	O
of	O
military	O
PPM	I-KP
guidelines,	O
but	O
that	O
command	O
enforcement	O
of	O
military	O
PPM	I-KP
guidelines	I-KP
is	O
low,	O
and	O
that	O
a	O
variety	O
of	O
less	O
effective	O
commercial	O
repellent	O
products	O
are	O
preferred	O
by	O
troops	O
over	O
military-issue	O
products.	O
	
[10,11]	O
Due	O
to	O
lack	O
of	O
compliance	O
with	O
PPM	I-KP
guidelines,	O
the	O
Armed	O
Forces	O
Epidemiological	O
Board	O
has	O
been	O
evaluating	O
how	O
the	O
ACIP	I-KP
Lyme	I-KP
disease	I-KP
vaccine	I-KP
recommendations	O
should	O
be	O
incorporated	O
into	O
DoD	O
vaccination	O
policies.	O
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
objective	O
epidemiological	I-KP
data	I-KP
that	O
would	O
better	O
characterize	O
the	O
risk	O
for	O
Lyme	I-KP
disease	I-KP
infection	I-KP
among	O
military	O
personnel.	O
	
The	O
seroepidemiology	I-KP
of	O
this	O
pathogen	I-KP
was	O
evaluated	O
in	O
a	O
randomly	O
selected	O
sample	O
of	O
U.S.	O
	
military	O
personnel,	O
and	O
demographic	O
characteristics	O
and	O
other	O
risk	O
factors	O
for	O
infection	O
were	O
assessed.	O
	
To	O
reduce	O
the	O
risk	O
of	O
tick	O
bites	O
while	O
in	O
the	O
field,	O
the	O
current	O
Department	O
of	O
Defense	O
(DoD)	O
repellent	B-KP
system	I-KP
was	O
adopted	O
in	O
1991.9	O
This	O
system	O
provides	O
specific	O
personal	B-KP
protective	I-KP
measure	I-KP
(PPM)	B-KP
guidelines	O
for	O
use	O
with	O
the	O
military	O
field	O
uniform,	O
which	O
provides	O
barrier	O
and	O
chemical	O
protection	O
against	O
arthropod	I-KP
borne	I-KP
infections.	O
	
However,	O
compliance	O
with	O
these	O
guidelines	O
has	O
been	O
demonstrated	O
to	O
be	O
inadequate,	O
even	O
under	O
conditions	O
of	O
high	O
risk	O
for	O
arthropod-related	I-KP
disease	I-KP
transmission	O
and	O
nuisance	O
bites.	O
	
Although	O
medical	O
threat	O
briefings	O
are	O
commonly	O
given	O
prior	O
to	O
field	O
missions,	O
studies	O
suggest	O
not	O
only	O
that	O
military	O
personnel	O
have	O
poor	O
knowledge	O
of	O
military	O
PPM	I-KP
guidelines,	O
but	O
that	O
command	O
enforcement	O
of	O
military	O
PPM	I-KP
guidelines	I-KP
is	O
low,	O
and	O
that	O
a	O
variety	O
of	O
less	O
effective	O
commercial	O
repellent	O
products	O
are	O
preferred	O
by	O
troops	O
over	O
military-issue	O
products.	O
	
[10,11]	O
Due	O
to	O
lack	O
of	O
compliance	O
with	O
PPM	I-KP
guidelines,	O
the	O
Armed	O
Forces	O
Epidemiological	O
Board	O
has	O
been	O
evaluating	O
how	O
the	O
ACIP	I-KP
Lyme	I-KP
disease	I-KP
vaccine	I-KP
recommendations	O
should	O
be	O
incorporated	O
into	O
DoD	O
vaccination	O
policies.	O
	
The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
objective	O
epidemiological	I-KP
data	I-KP
that	O
would	O
better	O
characterize	O
the	O
risk	O
for	O
Lyme	I-KP
disease	I-KP
infection	I-KP
among	O
military	O
personnel.	O
	
The	O
seroepidemiology	I-KP
of	O
this	O
pathogen	I-KP
was	O
evaluated	O
in	O
a	O
randomly	O
selected	O
sample	O
of	O
U.S.	O
	
military	O
personnel,	O
and	O
demographic	O
characteristics	O
and	O
other	O
risk	O
factors	O
for	O
infection	O
were	O
assessed.	O
	
Borrelia	B-KP
burgdorferi	I-KP
(Bb),	B-KP
a	O
motile,	O
helical	O
gram-negative	O
bacterium,	O
belongs	O
to	O
the	O
spirochete	I-KP
family.	O
	
It	O
stains	O
with	O
Giemsa	O
or	O
special	O
silver	O
stains	O
and	O
can	O
be	O
visualized	O
under	O
phase	O
contrast	O
or	O
dark	O
field	O
microscopy.	O
	
The	O
spirochete,	O
10-	O
to	O
30-pm	O
long	O
and	O
0.2-	O
to	O
0.3-~tm	O
wide,	O
has	O
a	B-KP
central	I-KP
protoplasmic	I-KP
cylinder	O
with	O
7	O
to	O
12	O
attached	O
periplasmic	I-KP
flagella	O
surrounded	O
by	O
an	B-KP
outer	I-KP
cell	I-KP
membrane	O
that	O
is	O
covered	O
by	O
a	I-KP
carbohydrate-containing	I-KP
slime	I-KP
layer.	O
	
Bb	O
contains	O
chromosomal	I-KP
DNA	O
and	B-KP
extrachromosomal	I-KP
double-stranded	I-KP
DNA	O
in	O
the	O
form	O
of	O
distinct	O
supercoiled	I-KP
circular	I-KP
and	I-KP
linear	I-KP
plasmids.	O
	
Both	O
chromosomal	O
and	B-KP
plasmid	I-KP
DNA	I-KP
code	O
for	O
proteins,	O
some	O
of	O
which	O
are	O
not	O
unique	O
to	I-KP
Bb.	O
	
These	O
include	O
p41	O
(flagellin-a	O
protein	O
common	O
to	O
spirochetes)	O
and	B-KP
p58-60,	O
p66,	B-KP
p68,	B-KP
p71,	O
and	I-KP
p73	B-KP
(heat-shock	I-KP
proteins).	O
	
These	O
conserved	O
but	O
nonspecific	O
borrelia	I-KP
proteins	O
cause	B-KP
serological	I-KP
cross-reactivity,	O
as	O
discussed	O
later.	O
	
Bb-unique	O
proteins	O
include:	O
plasmid-coded	O
outer	I-KP
surface	I-KP
lipoproteins	O
(Osp)	O
31	O
kDa	I-KP
(OspA);	O
34	O
kDA	I-KP
(OspB);	O
23	O
kDA	I-KP
(OspC);	O
newly	O
recognized	O
proteins	O
OspD,	B-KP
OspE,	B-KP
OspF;	O
and	O
p93,	O
a	O
protein	O
that	O
appears	O
to	O
be	I-KP
a	I-KP
protoplasmic	I-KP
cylinder	I-KP
antigen,	O
and	O
p39,	O
a	O
unique	B-KP
lipoprotein.	O
	
[17]	O
Borrelia	B-KP
burgdorferi	I-KP
(Bb),	B-KP
a	O
motile,	O
helical	O
gram-negative	O
bacterium,	O
belongs	O
to	O
the	O
spirochete	I-KP
family.	O
	
It	O
stains	O
with	O
Giemsa	O
or	O
special	O
silver	O
stains	O
and	O
can	O
be	O
visualized	O
under	O
phase	O
contrast	O
or	O
dark	O
field	O
microscopy.	O
	
The	O
spirochete,	O
10-	O
to	O
30-pm	O
long	O
and	O
0.2-	O
to	O
0.3-~tm	O
wide,	O
has	O
a	B-KP
central	I-KP
protoplasmic	I-KP
cylinder	O
with	O
7	O
to	O
12	O
attached	O
periplasmic	I-KP
flagella	O
surrounded	O
by	O
an	B-KP
outer	I-KP
cell	I-KP
membrane	O
that	O
is	O
covered	O
by	O
a	I-KP
carbohydrate-containing	I-KP
slime	I-KP
layer.	O
	
Bb	O
contains	O
chromosomal	I-KP
DNA	O
and	B-KP
extrachromosomal	I-KP
double-stranded	I-KP
DNA	O
in	O
the	O
form	O
of	O
distinct	O
supercoiled	I-KP
circular	I-KP
and	I-KP
linear	I-KP
plasmids.	O
	
Both	O
chromosomal	O
and	B-KP
plasmid	I-KP
DNA	I-KP
code	O
for	O
proteins,	O
some	O
of	O
which	O
are	O
not	O
unique	O
to	I-KP
Bb.	O
	
These	O
include	O
p41	O
(flagellin-a	O
protein	O
common	O
to	O
spirochetes)	O
and	B-KP
p58-60,	O
p66,	B-KP
p68,	B-KP
p71,	O
and	I-KP
p73	B-KP
(heat-shock	I-KP
proteins).	O
	
These	O
conserved	O
but	O
nonspecific	O
borrelia	I-KP
proteins	O
cause	B-KP
serological	I-KP
cross-reactivity,	O
as	O
discussed	O
later.	O
	
Bb-unique	O
proteins	O
include:	O
plasmid-coded	O
outer	I-KP
surface	I-KP
lipoproteins	O
(Osp)	O
31	O
kDa	I-KP
(OspA);	O
34	O
kDA	I-KP
(OspB);	O
23	O
kDA	I-KP
(OspC);	O
newly	O
recognized	O
proteins	O
OspD,	B-KP
OspE,	B-KP
OspF;	O
and	O
p93,	O
a	O
protein	O
that	O
appears	O
to	O
be	I-KP
a	I-KP
protoplasmic	I-KP
cylinder	I-KP
antigen,	O
and	O
p39,	O
a	O
unique	B-KP
lipoprotein.	O
	
[17]	O
Facial	B-KP
nerve	I-KP
palsy.	I-KP
	
Facial	B-KP
nerve	I-KP
palsy	I-KP
(FNP),	B-KP
the	O
most	O
frequent	O
neurological	O
complication	O
in	O
children	O
[37,43,53,54,57,61,64,75,76]	O
can	O
be	O
the	O
presenting	O
manifestation	O
of	O
Lyme	I-KP
disease.	O
	
In	O
large	O
series,	O
about	O
one	O
third	O
of	O
patients	O
with	O
Lyme	I-KP
disease-associated	I-KP
FNP	I-KP
report	O
antecedent	O
EM.	O
	
When	O
a	O
tick	O
bite	O
is	O
recalled	O
or	O
EM	I-KP
occurs	O
on	O
the	O
face	O
or	O
neck,	O
FNP	I-KP
usually	O
affects	O
the	O
same	O
side.	O
	
Bilateral	O
involvement	O
is	O
common,	O
involving	O
6%	O
to	O
37%	O
of	O
patients.	O
	
[19,53,55-57,75-79]	O
Lyme	I-KP
disease-associated	I-KP
FNP	I-KP
displays	O
a	O
distinct	O
seasonal	O
pattern,	O
from	O
May	O
to	O
November,	O
with	O
peak	O
incidence	O
in	O
the	O
summer	O
months.\nEuropean	O
studies	O
indicate	O
that	O
Lyme	I-KP
neuroborreliosis	I-KP
is	O
the	O
most	O
common	O
cause	O
of	O
FNP	I-KP
in	O
children	O
who	O
live	O
in	O
endemic	I-KP
areas.	O
	
[14,15,54,59,75,76]	O
Overall,	O
more	O
than	O
one	O
third	O
(34%	O
to	O
43%)	O
of	O
children	O
with	O
FNP	I-KP
were	O
found	O
to	O
have	O
neuroborreliosis	I-KP
as	O
indicated	O
by	O
detection	O
of	O
CSF	I-KP
Bb-specific	I-KP
IgM	I-KP
antibodies.	O
	
54,59,75.76	O
Prospective	O
studies	O
also	O
reveal	O
that	O
the	O
percentage	O
rises	O
to	O
more	O
than	O
50%	O
during	O
the	O
summer	O
months.	O
	
59,76	O
This	O
contrasts	O
with	O
adult	O
studies	O
in	O
which	O
the	O
relative	O
frequency	O
of	O
Lyme	I-KP
disease-associated	I-KP
FNP	I-KP
is	O
estimated	O
to	O
be	O
20%	O
to	O
25%)	O
[14,80]	O
Facial	B-KP
nerve	I-KP
palsy.	I-KP
	
Facial	B-KP
nerve	I-KP
palsy	I-KP
(FNP),	B-KP
the	O
most	O
frequent	O
neurological	O
complication	O
in	O
children	O
[37,43,53,54,57,61,64,75,76]	O
can	O
be	O
the	O
presenting	O
manifestation	O
of	O
Lyme	I-KP
disease.	O
	
In	O
large	O
series,	O
about	O
one	O
third	O
of	O
patients	O
with	O
Lyme	I-KP
disease-associated	I-KP
FNP	I-KP
report	O
antecedent	O
EM.	O
	
When	O
a	O
tick	O
bite	O
is	O
recalled	O
or	O
EM	I-KP
occurs	O
on	O
the	O
face	O
or	O
neck,	O
FNP	I-KP
usually	O
affects	O
the	O
same	O
side.	O
	
Bilateral	O
involvement	O
is	O
common,	O
involving	O
6%	O
to	O
37%	O
of	O
patients.	O
	
[19,53,55-57,75-79]	O
Lyme	I-KP
disease-associated	I-KP
FNP	I-KP
displays	O
a	O
distinct	O
seasonal	O
pattern,	O
from	O
May	O
to	O
November,	O
with	O
peak	O
incidence	O
in	O
the	O
summer	O
months.\nEuropean	O
studies	O
indicate	O
that	O
Lyme	I-KP
neuroborreliosis	I-KP
is	O
the	O
most	O
common	O
cause	O
of	O
FNP	I-KP
in	O
children	O
who	O
live	O
in	O
endemic	I-KP
areas.	O
	
[14,15,54,59,75,76]	O
Overall,	O
more	O
than	O
one	O
third	O
(34%	O
to	O
43%)	O
of	O
children	O
with	O
FNP	I-KP
were	O
found	O
to	O
have	O
neuroborreliosis	I-KP
as	O
indicated	O
by	O
detection	O
of	O
CSF	I-KP
Bb-specific	I-KP
IgM	I-KP
antibodies.	O
	
54,59,75.76	O
Prospective	O
studies	O
also	O
reveal	O
that	O
the	O
percentage	O
rises	O
to	O
more	O
than	O
50%	O
during	O
the	O
summer	O
months.	O
	
59,76	O
This	O
contrasts	O
with	O
adult	O
studies	O
in	O
which	O
the	O
relative	O
frequency	O
of	O
Lyme	I-KP
disease-associated	I-KP
FNP	I-KP
is	O
estimated	O
to	O
be	O
20%	O
to	O
25%)	O
[14,80]	O
Aseptic	B-KP
meningitis.	I-KP
	
In	O
the	O
absence	O
of	O
EM	B-KP
or	O
FNP,	B-KP
Lyme	B-KP
meningitis	I-KP
may	O
be	O
indistinguishable	O
from	O
aseptic	O
(viral)	O
meningitis.	B-KP
	
In	O
both	O
conditions,	O
patients	O
may	O
have	O
headache,	B-KP
neck	B-KP
stiffness,	I-KP
and	O
fever.	B-KP
	
CSF	B-KP
cell	I-KP
count	I-KP
and	O
chemistries	O
are	O
identical,	O
and	O
both	O
have	O
a	O
seasonal	O
occurrence.	O
	
If	O
meningitis	B-KP
develops	O
in	O
the	O
spring,	O
summer,	O
or	O
fall,	O
and	O
the	O
child	O
lives	O
in	O
or	O
has	O
recently	O
traveled	O
to	O
an	O
endemic	B-KP
area,	I-KP
and	O
Lyme	B-KP
disease	I-KP
is	O
suspected,	O
serum	O
and	O
CSF	B-KP
anti-B,	I-KP
burgdorferi	B-KP
antibodies	I-KP
should	O
be	O
obtained.\nFacial	O
nerve	I-KP
palsy.	I-KP
	
The	O
clinical	O
features	O
of	O
Lyme-associated	B-KP
facial	I-KP
nerve	I-KP
palsy	I-KP
are	O
similar	O
to	O
those	O
of	O
idiopathic	B-KP
Bell's	I-KP
palsy.	O
	
In	O
the	O
absence	O
of	O
EM,	O
Lyme	I-KP
disease	I-KP
should	O
be	O
considered	O
if	O
the	O
child	O
lives	O
in	O
or	O
has	O
recently	O
traveled	O
to	O
an	O
endemic	I-KP
area	I-KP
and	O
the	O
onset	O
of	O
paralysis	O
is	O
in	O
the	O
spring,	O
summer,	O
or	O
fall.	O
	
Anti-B.	I-KP
	
burgdorferi	I-KP
antibody	I-KP
titers	O
in	O
serum	O
should	O
be	O
obtained.	O
	
If	O
positive,	O
CSF	I-KP
examination	O
to	O
detect	O
occult	I-KP
meningitis	I-KP
is	O
recommended	O
by	O
many.	O
	
[54,72,75,98]	O
If	O
negative,	O
we	O
repeat	O
serological	I-KP
studies	I-KP
in	O
6	O
to	O
8	O
weeks.\nOptic	O
nerve	I-KP
edema/optic	O
neuritis/increased	O
intracranial	O
pressure.	O
	
The	O
above	O
also	O
applies	O
for	O
the	O
child	O
who	O
has	O
Lyme	I-KP
disease	I-KP
exposure,	O
without	O
a	O
history	O
of	O
EM,	O
and	O
presents	O
with	O
optic	I-KP
neuritis	I-KP
or	O
optic	I-KP
nerve	I-KP
edema	I-KP
with	O
or	O
without	O
other	O
signs	O
of	O
increased	O
intracranial	O
pressure.	O
	
Other	O
causes	O
should	O
be	O
excluded	O
by	O
appropriate	O
studies.	O
	
Aseptic	B-KP
meningitis.	I-KP
	
In	O
the	O
absence	O
of	O
EM	B-KP
or	O
FNP,	B-KP
Lyme	B-KP
meningitis	I-KP
may	O
be	O
indistinguishable	O
from	O
aseptic	O
(viral)	O
meningitis.	B-KP
	
In	O
both	O
conditions,	O
patients	O
may	O
have	O
headache,	B-KP
neck	B-KP
stiffness,	I-KP
and	O
fever.	B-KP
	
CSF	B-KP
cell	I-KP
count	I-KP
and	O
chemistries	O
are	O
identical,	O
and	O
both	O
have	O
a	O
seasonal	O
occurrence.	O
	
If	O
meningitis	B-KP
develops	O
in	O
the	O
spring,	O
summer,	O
or	O
fall,	O
and	O
the	O
child	O
lives	O
in	O
or	O
has	O
recently	O
traveled	O
to	O
an	O
endemic	B-KP
area,	I-KP
and	O
Lyme	B-KP
disease	I-KP
is	O
suspected,	O
serum	O
and	O
CSF	B-KP
anti-B,	I-KP
burgdorferi	B-KP
antibodies	I-KP
should	O
be	O
obtained.\nFacial	O
nerve	I-KP
palsy.	I-KP
	
The	O
clinical	O
features	O
of	O
Lyme-associated	B-KP
facial	I-KP
nerve	I-KP
palsy	I-KP
are	O
similar	O
to	O
those	O
of	O
idiopathic	B-KP
Bell's	I-KP
palsy.	O
	
In	O
the	O
absence	O
of	O
EM,	O
Lyme	I-KP
disease	I-KP
should	O
be	O
considered	O
if	O
the	O
child	O
lives	O
in	O
or	O
has	O
recently	O
traveled	O
to	O
an	O
endemic	I-KP
area	I-KP
and	O
the	O
onset	O
of	O
paralysis	O
is	O
in	O
the	O
spring,	O
summer,	O
or	O
fall.	O
	
Anti-B.	I-KP
	
burgdorferi	I-KP
antibody	I-KP
titers	O
in	O
serum	O
should	O
be	O
obtained.	O
	
If	O
positive,	O
CSF	I-KP
examination	O
to	O
detect	O
occult	I-KP
meningitis	I-KP
is	O
recommended	O
by	O
many.	O
	
[54,72,75,98]	O
If	O
negative,	O
we	O
repeat	O
serological	I-KP
studies	I-KP
in	O
6	O
to	O
8	O
weeks.\nOptic	O
nerve	I-KP
edema/optic	O
neuritis/increased	O
intracranial	O
pressure.	O
	
The	O
above	O
also	O
applies	O
for	O
the	O
child	O
who	O
has	O
Lyme	I-KP
disease	I-KP
exposure,	O
without	O
a	O
history	O
of	O
EM,	O
and	O
presents	O
with	O
optic	I-KP
neuritis	I-KP
or	O
optic	I-KP
nerve	I-KP
edema	I-KP
with	O
or	O
without	O
other	O
signs	O
of	O
increased	O
intracranial	O
pressure.	O
	
Other	O
causes	O
should	O
be	O
excluded	O
by	O
appropriate	O
studies.	O
	
Lyme	B-KP
disease	I-KP
(LD)	B-KP
is	O
a	O
tick-borne	O
infection	O
caused	O
by	O
the	O
spirochete	I-KP
Borrelia	I-KP
burgdorferi.	O
	
Primary	O
LD	I-KP
commonly	O
presents	O
as	O
a	O
flu-like	O
ifiness	O
in	O
children,	O
sometimes	O
accompanied	O
by	O
the	O
diagnostic	O
rash	O
known	O
as	O
erythema	I-KP
migrans	I-KP
(EM).	B-KP
	
[1]	O
Rheumatologic,	O
neurologic,	O
dermatologic,	O
or	O
cardiologic	I-KP
manifestations	O
in	O
systemic	O
LD	I-KP
may	O
follow	O
the	O
primary	O
infection	O
by	O
weeks	O
or	O
months,	O
or	O
they	O
may	O
be	O
the	O
initial	O
presentation	O
of	O
LD.	O
	
A	O
wide	O
variety	O
of	O
neurologic	I-KP
syndromes	I-KP
have	O
been	O
reported	O
in	O
both	O
children	O
and	O
adults	O
with	O
LD,	O
ranging	O
from	O
acute	I-KP
myositis	I-KP
to	O
chronic	I-KP
encephalopathy.	O
	
However,	O
facial	I-KP
palsy	I-KP
and	O
aseptic	I-KP
meningitis	I-KP
are	O
the	O
most	O
commonly	O
reported	O
neurologic	O
manifestations.	O
	
[2]\nThe	O
nonspecificity	O
of	O
clinical	O
presentations	O
and	O
limitations	O
in	O
laboratory	O
diagnosis	O
complicate	O
the	O
diagnosis	O
of	O
neuroborreliosis.	O
	
While	O
Lyme	I-KP
serology	I-KP
is	O
considered	O
highly	O
sensitive	O
in	O
systemic	I-KP
LD,	O
false	O
positives	O
may	O
be	O
due	O
to	O
asymptomatic	I-KP
seroconversion,	O
antibodies	O
to	O
oral	I-KP
spirochetes,	O
prior	O
infection,	O
or	O
immunologic	O
cross	O
reaction	O
to	O
other	O
pathogens.	O
	
Several	O
authors	O
have	O
emphasized	O
the	O
precedence	O
of	O
clinical	O
criteria	O
for	O
making	O
diagnostic	O
and	O
treatment	O
decisions	O
in	O
patients	O
with	O
suspected	O
LD.	O
	
[3-5]	O
When	O
new	O
neurologic	O
symptoms	O
appear	O
in	O
concert	O
with	O
other	O
clinical	O
manifestations	O
typical	O
of	O
LD,	O
the	O
diagnosis	O
of	O
neuroborreliosis	I-KP
is	O
usually	O
secure.\nBecause	O
individuals	O
with	O
systemic	O
signs	O
of	O
LD	I-KP
are	O
usually	O
seropositive,	O
we	O
reviewed	O
clinical	O
data	O
in	O
seropositive	I-KP
children	O
to	O
determine	O
1)	O
how	O
often	O
the	O
initial	O
clinical	O
evaluation	O
permitted	O
a	O
diagnosis	O
of	O
neuroborreliosis,	O
and	O
2)	O
the	O
range	O
of	O
neurologic	O
signs	O
in	O
children	O
with	O
positive	O
Lyme	I-KP
serology.	O
	
Lyme	B-KP
disease	I-KP
(LD)	B-KP
is	O
a	O
tick-borne	O
infection	O
caused	O
by	O
the	O
spirochete	I-KP
Borrelia	I-KP
burgdorferi.	O
	
Primary	O
LD	I-KP
commonly	O
presents	O
as	O
a	O
flu-like	O
ifiness	O
in	O
children,	O
sometimes	O
accompanied	O
by	O
the	O
diagnostic	O
rash	O
known	O
as	O
erythema	I-KP
migrans	I-KP
(EM).	B-KP
	
[1]	O
Rheumatologic,	O
neurologic,	O
dermatologic,	O
or	O
cardiologic	I-KP
manifestations	O
in	O
systemic	O
LD	I-KP
may	O
follow	O
the	O
primary	O
infection	O
by	O
weeks	O
or	O
months,	O
or	O
they	O
may	O
be	O
the	O
initial	O
presentation	O
of	O
LD.	O
	
A	O
wide	O
variety	O
of	O
neurologic	I-KP
syndromes	I-KP
have	O
been	O
reported	O
in	O
both	O
children	O
and	O
adults	O
with	O
LD,	O
ranging	O
from	O
acute	I-KP
myositis	I-KP
to	O
chronic	I-KP
encephalopathy.	O
	
However,	O
facial	I-KP
palsy	I-KP
and	O
aseptic	I-KP
meningitis	I-KP
are	O
the	O
most	O
commonly	O
reported	O
neurologic	O
manifestations.	O
	
[2]\nThe	O
nonspecificity	O
of	O
clinical	O
presentations	O
and	O
limitations	O
in	O
laboratory	O
diagnosis	O
complicate	O
the	O
diagnosis	O
of	O
neuroborreliosis.	O
	
While	O
Lyme	I-KP
serology	I-KP
is	O
considered	O
highly	O
sensitive	O
in	O
systemic	I-KP
LD,	O
false	O
positives	O
may	O
be	O
due	O
to	O
asymptomatic	I-KP
seroconversion,	O
antibodies	O
to	O
oral	I-KP
spirochetes,	O
prior	O
infection,	O
or	O
immunologic	O
cross	O
reaction	O
to	O
other	O
pathogens.	O
	
Several	O
authors	O
have	O
emphasized	O
the	O
precedence	O
of	O
clinical	O
criteria	O
for	O
making	O
diagnostic	O
and	O
treatment	O
decisions	O
in	O
patients	O
with	O
suspected	O
LD.	O
	
[3-5]	O
When	O
new	O
neurologic	O
symptoms	O
appear	O
in	O
concert	O
with	O
other	O
clinical	O
manifestations	O
typical	O
of	O
LD,	O
the	O
diagnosis	O
of	O
neuroborreliosis	I-KP
is	O
usually	O
secure.\nBecause	O
individuals	O
with	O
systemic	O
signs	O
of	O
LD	I-KP
are	O
usually	O
seropositive,	O
we	O
reviewed	O
clinical	O
data	O
in	O
seropositive	I-KP
children	O
to	O
determine	O
1)	O
how	O
often	O
the	O
initial	O
clinical	O
evaluation	O
permitted	O
a	O
diagnosis	O
of	O
neuroborreliosis,	O
and	O
2)	O
the	O
range	O
of	O
neurologic	O
signs	O
in	O
children	O
with	O
positive	O
Lyme	I-KP
serology.	O
	
Arthritis	O
is	O
the	O
most	O
common	O
late	O
manifestation	O
of	O
Lyme	B-KP
disease	I-KP
and	O
in	O
one	O
study	O
(7)	O
was	O
documented	O
to	O
occur	O
in	O
60%	O
of	O
patients	O
in	O
whom	O
infection	O
was	O
not	O
treated	O
at	O
earlier	O
stages,	O
usually	O
developing	O
many	O
months	O
(average	O
6	O
months)	O
after	O
infection.	O
	
Most	O
patients	O
present	O
with	O
an	O
oligoarticular	B-KP
inflammatory	I-KP
arthritis	I-KP
affecting	O
1	O
or	O
more	O
large	O
joints,	O
especially	O
the	O
knee	O
[7]	O
(Table	O
2).	O
	
The	O
arthritis	O
can	O
be	O
migratory,	O
but	O
involvement	O
of	O
5	O
joints	O
is	O
unusual.	O
	
Other	O
signs	O
may	O
include	O
bursitis	B-KP
or	O
tendinitis	B-KP
and	O
temporomandibular	B-KP
joint	I-KP
pain.	I-KP
	
Children	O
often	O
present	O
with	O
more	O
acute	B-KP
arthritis	I-KP
than	O
adults,	O
with	O
fever	O
and	O
elevated	O
peripheral	O
blood	O
and	O
SF	B-KP
white	I-KP
blood	I-KP
cell	I-KP
counts,	I-KP
suggesting	O
septic	B-KP
arthritis	I-KP
[10,11].	O
	
Alternatively,	O
patients	O
with	O
Lyme	B-KP
arthritis	I-KP
may	O
have	O
no	O
other	O
symptoms	O
of	O
systemic	B-KP
infection	I-KP
and	O
present	O
with	O
a	O
large	O
joint	B-KP
effusion	I-KP
with	O
more	O
stiffness	O
than	O
pain.	O
	
Baker’s	B-KP
cysts	I-KP
can	O
form	O
and	O
rupture.\nWithout	O
antibiotic	B-KP
treatment,	I-KP
Lyme	B-KP
arthritis	I-KP
may	O
wax	O
and	O
wane,	O
with	O
an	O
episode	O
of	O
synovitis	B-KP
lasting	O
weeks	O
to	O
months;	O
episodes	O
can	O
decrease	O
in	O
frequency	O
and	O
resolve	O
over	O
time	O
[7].	O
	
A	O
minority	O
(10%)	O
of	O
patients	O
develop	O
synovitis	B-KP
of	O
a	O
joint	O
that	O
persists	O
despite	O
multiple	O
courses	O
of	O
antibiotics,	B-KP
an	O
entity	O
termed	O
“antibiotic-refractory	B-KP
Lyme	I-KP
arthritis”	O
[7].	O
	
The	O
genetics	O
of	O
both	O
the	O
host	O
(12,13)	O
and	O
the	O
strain	O
of	O
B	I-KP
burgdorferi	I-KP
causing	O
the	O
infection	O
(14)	O
appear	O
to	O
play	O
a	O
role	O
in	O
determining	O
this	O
outcome,	O
which	O
shares	O
features	O
with	O
other	O
forms	O
of	O
nonseptic	I-KP
inflammatory	I-KP
arthritis	I-KP
(Table	O
2).	O
	
Arthritis	O
is	O
the	O
most	O
common	O
late	O
manifestation	O
of	O
Lyme	B-KP
disease	I-KP
and	O
in	O
one	O
study	O
(7)	O
was	O
documented	O
to	O
occur	O
in	O
60%	O
of	O
patients	O
in	O
whom	O
infection	O
was	O
not	O
treated	O
at	O
earlier	O
stages,	O
usually	O
developing	O
many	O
months	O
(average	O
6	O
months)	O
after	O
infection.	O
	
Most	O
patients	O
present	O
with	O
an	O
oligoarticular	B-KP
inflammatory	I-KP
arthritis	I-KP
affecting	O
1	O
or	O
more	O
large	O
joints,	O
especially	O
the	O
knee	O
[7]	O
(Table	O
2).	O
	
The	O
arthritis	O
can	O
be	O
migratory,	O
but	O
involvement	O
of	O
5	O
joints	O
is	O
unusual.	O
	
Other	O
signs	O
may	O
include	O
bursitis	B-KP
or	O
tendinitis	B-KP
and	O
temporomandibular	B-KP
joint	I-KP
pain.	I-KP
	
Children	O
often	O
present	O
with	O
more	O
acute	B-KP
arthritis	I-KP
than	O
adults,	O
with	O
fever	O
and	O
elevated	O
peripheral	O
blood	O
and	O
SF	B-KP
white	I-KP
blood	I-KP
cell	I-KP
counts,	I-KP
suggesting	O
septic	B-KP
arthritis	I-KP
[10,11].	O
	
Alternatively,	O
patients	O
with	O
Lyme	B-KP
arthritis	I-KP
may	O
have	O
no	O
other	O
symptoms	O
of	O
systemic	B-KP
infection	I-KP
and	O
present	O
with	O
a	O
large	O
joint	B-KP
effusion	I-KP
with	O
more	O
stiffness	O
than	O
pain.	O
	
Baker’s	B-KP
cysts	I-KP
can	O
form	O
and	O
rupture.\nWithout	O
antibiotic	B-KP
treatment,	I-KP
Lyme	B-KP
arthritis	I-KP
may	O
wax	O
and	O
wane,	O
with	O
an	O
episode	O
of	O
synovitis	B-KP
lasting	O
weeks	O
to	O
months;	O
episodes	O
can	O
decrease	O
in	O
frequency	O
and	O
resolve	O
over	O
time	O
[7].	O
	
A	O
minority	O
(10%)	O
of	O
patients	O
develop	O
synovitis	B-KP
of	O
a	O
joint	O
that	O
persists	O
despite	O
multiple	O
courses	O
of	O
antibiotics,	B-KP
an	O
entity	O
termed	O
“antibiotic-refractory	B-KP
Lyme	I-KP
arthritis”	O
[7].	O
	
The	O
genetics	O
of	O
both	O
the	O
host	O
(12,13)	O
and	O
the	O
strain	O
of	O
B	I-KP
burgdorferi	I-KP
causing	O
the	O
infection	O
(14)	O
appear	O
to	O
play	O
a	O
role	O
in	O
determining	O
this	O
outcome,	O
which	O
shares	O
features	O
with	O
other	O
forms	O
of	O
nonseptic	I-KP
inflammatory	I-KP
arthritis	I-KP
(Table	O
2).	O
	
Patients	O
with	O
Lyme	B-KP
arthritis	I-KP
are	O
initially	O
treated	O
with	O
a	O
4-week	O
course	O
of	O
oral	B-KP
antibiotics.	I-KP
	
Nonsteroidal	B-KP
antiinflammatory	I-KP
drugs	I-KP
are	O
often	O
used	O
to	O
ameliorate	O
symptoms	O
during	O
and	O
after	O
antibiotic	B-KP
treatment.	I-KP
	
Incomplete	O
resolution	O
of	O
arthritis	O
at	O
4	O
weeks	O
has	O
been	O
observed	O
in	O
40%	O
of	O
patients,	O
and	O
an	O
additional	O
course	O
of	O
oral	O
or	O
intravenous	O
antibiotics	O
may	O
be	O
necessary	O
(37).	O
	
No	O
controlled	O
trials	O
are	O
available	O
to	O
guide	O
the	O
decision	O
regarding	O
whether	O
further	O
antibiotics	B-KP
should	O
be	O
prescribed	O
versus	O
antiinflammatory	O
medications,	O
including	O
intraarticular	B-KP
corticosteroids,	I-KP
to	O
hasten	O
arthritis	O
resolution.	O
	
Arthritis	O
may	O
be	O
considered	O
refractory	O
to	O
antibiotics	O
if	O
it	O
persists	O
for	O
2	O
months	O
after	O
a	O
course	O
of	O
intravenous	B-KP
antibiotics	I-KP
or	O
1	O
month	O
after	O
two	O
4-week	O
courses	O
of	O
oral	B-KP
antibiotics	I-KP
(if	O
parenteral	O
therapy	O
is	O
not	O
possible)	O
and	O
the	O
results	O
of	O
PCR	B-KP
testing	I-KP
of	O
SF	B-KP
are	O
negative	O
for	O
borrelia	B-KP
DNA	I-KP
[37].	O
	
Antibiotic-refractory	B-KP
Lyme	I-KP
arthritis	I-KP
is	O
not	O
likely	O
due	O
to	O
persistent	O
infection	O
because	O
intraarticular	B-KP
steroids	I-KP
[36]	O
and/or	O
DMARD	B-KP
therapies	I-KP
(hydroxychloroquine,	O
sulfasalazine,	O
or	O
methotrexate),	O
and	O
rarely	O
TNF	B-KP
antagonists,	I-KP
have	O
been	O
used	O
successfully	O
without	O
signs	O
of	O
recrudescent	O
infection	O
in	O
the	O
joint	O
or	O
elsewhere	O
[35].	O
	
Synovectomy	B-KP
can	O
be	O
curative	O
if	O
most	O
of	O
the	O
synovial	B-KP
tissue	I-KP
is	O
removed;	O
excised	O
synovial	B-KP
tissue	I-KP
has	O
been	O
uniformly	O
negative	O
for	O
B	B-KP
burgdorferi	I-KP
by	O
PCR	O
and	O
culture	O
[41].	O
	
Patients	O
with	O
Lyme	B-KP
arthritis	I-KP
are	O
initially	O
treated	O
with	O
a	O
4-week	O
course	O
of	O
oral	B-KP
antibiotics.	I-KP
	
Nonsteroidal	B-KP
antiinflammatory	I-KP
drugs	I-KP
are	O
often	O
used	O
to	O
ameliorate	O
symptoms	O
during	O
and	O
after	O
antibiotic	B-KP
treatment.	I-KP
	
Incomplete	O
resolution	O
of	O
arthritis	O
at	O
4	O
weeks	O
has	O
been	O
observed	O
in	O
40%	O
of	O
patients,	O
and	O
an	O
additional	O
course	O
of	O
oral	O
or	O
intravenous	O
antibiotics	O
may	O
be	O
necessary	O
(37).	O
	
No	O
controlled	O
trials	O
are	O
available	O
to	O
guide	O
the	O
decision	O
regarding	O
whether	O
further	O
antibiotics	B-KP
should	O
be	O
prescribed	O
versus	O
antiinflammatory	O
medications,	O
including	O
intraarticular	B-KP
corticosteroids,	I-KP
to	O
hasten	O
arthritis	O
resolution.	O
	
Arthritis	O
may	O
be	O
considered	O
refractory	O
to	O
antibiotics	O
if	O
it	O
persists	O
for	O
2	O
months	O
after	O
a	O
course	O
of	O
intravenous	B-KP
antibiotics	I-KP
or	O
1	O
month	O
after	O
two	O
4-week	O
courses	O
of	O
oral	B-KP
antibiotics	I-KP
(if	O
parenteral	O
therapy	O
is	O
not	O
possible)	O
and	O
the	O
results	O
of	O
PCR	B-KP
testing	I-KP
of	O
SF	B-KP
are	O
negative	O
for	O
borrelia	B-KP
DNA	I-KP
[37].	O
	
Antibiotic-refractory	B-KP
Lyme	I-KP
arthritis	I-KP
is	O
not	O
likely	O
due	O
to	O
persistent	O
infection	O
because	O
intraarticular	B-KP
steroids	I-KP
[36]	O
and/or	O
DMARD	B-KP
therapies	I-KP
(hydroxychloroquine,	O
sulfasalazine,	O
or	O
methotrexate),	O
and	O
rarely	O
TNF	B-KP
antagonists,	I-KP
have	O
been	O
used	O
successfully	O
without	O
signs	O
of	O
recrudescent	O
infection	O
in	O
the	O
joint	O
or	O
elsewhere	O
[35].	O
	
Synovectomy	B-KP
can	O
be	O
curative	O
if	O
most	O
of	O
the	O
synovial	B-KP
tissue	I-KP
is	O
removed;	O
excised	O
synovial	B-KP
tissue	I-KP
has	O
been	O
uniformly	O
negative	O
for	O
B	B-KP
burgdorferi	I-KP
by	O
PCR	O
and	O
culture	O
[41].	O
	
The	O
appearance	O
of	O
new	O
or	O
recurrent	O
objective	O
signs	O
of	O
Lyme	B-KP
disease	I-KP
after	O
antibiotic	B-KP
therapy	I-KP
should	O
prompt	O
evaluation	O
for	O
reinfection	O
or	O
incomplete	O
treatment.	O
	
A	O
recent	O
study	O
in	O
which	O
the	O
causative	O
strain	O
of	O
B	B-KP
burgdorferi	I-KP
was	O
cultured	O
from	O
EM	B-KP
lesions	I-KP
showed	O
that	O
recurrent	O
EM	B-KP
after	O
treatment	O
was	O
due	O
to	O
reinfection	O
rather	O
than	O
a	O
relapse	O
of	O
the	O
previously	O
treated	O
infection	O
[46].\nIn	O
25%	O
of	O
patients	O
with	O
EM,	B-KP
clinical	O
disease	O
resolves	O
but	O
fatigue,	O
cognitive	O
problems,	O
or	O
joint	O
and	O
muscle	O
aches	O
persist	O
at	O
3	O
months	O
after	O
treatment;	O
this	O
percentage	O
decreases	O
to	O
10%	O
at	O
6	O
months.	O
	
Posttreatment	B-KP
Lyme	I-KP
disease	I-KP
syndrome	I-KP
(PTLDS)	B-KP
refers	O
to	O
such	O
symptoms	O
that	O
last	O
for	O
6	O
months	O
after	O
a	O
documented	O
episode	O
of	O
Lyme	O
disease	O
and	O
are	O
disabling.	O
	
The	O
frequency	O
with	O
which	O
PTLDS	I-KP
occurs	O
is	O
believed	O
to	O
be	O
substantially	O
below	O
10%.	O
	
PTLDS	I-KP
should	O
not	O
be	O
confused	O
with	O
"chronic	B-KP
Lyme	I-KP
disease."	O
This	O
name	O
originally	O
referred	O
to	O
late	O
manifestations	O
of	O
the	O
disease,	O
but	O
has	O
been	O
usurped	O
as	O
a	O
label	O
for	O
clinical	O
syndromes	O
that	O
may	O
or	O
may	O
not	O
be	O
associated	O
with	O
previous	O
Lyme	O
borrelia	O
exposure	O
[47].\nThe	O
reasons	O
for	O
persistence	O
of	O
symptoms	O
in	O
some	O
patients	O
after	O
treatment	O
for	O
Lyme	O
disease	O
are	O
not	O
known.	O
	
Theories	O
include	O
residual	O
damage	O
to	O
tissue,	O
slow	O
resolution	O
of	O
the	O
inflammatory	O
state,	O
and/or	O
a	O
form	O
of	O
cytokine-induced	O
sickness	O
behavior	O
due	O
to	O
previously	O
high	O
levels	O
of	O
circulating	O
cytokines.	O
	
Systemic	I-KP
inflammatory	I-KP
cytokines	I-KP
exert	O
adverse	O
effects	O
on	O
neurobehavioral	O
function	O
in	O
other	O
conditions,	O
independent	O
of	O
a	B-KP
central	I-KP
nervous	I-KP
system	I-KP
infection	O
[8].	O
	
Nonspecific	O
symptoms	O
such	O
as	O
fatigue	O
and	O
pain	O
are	O
common	O
in	O
the	O
general	O
population	O
as	O
well.	O
	
The	O
appearance	O
of	O
new	O
or	O
recurrent	O
objective	O
signs	O
of	O
Lyme	B-KP
disease	I-KP
after	O
antibiotic	B-KP
therapy	I-KP
should	O
prompt	O
evaluation	O
for	O
reinfection	O
or	O
incomplete	O
treatment.	O
	
A	O
recent	O
study	O
in	O
which	O
the	O
causative	O
strain	O
of	O
B	B-KP
burgdorferi	I-KP
was	O
cultured	O
from	O
EM	B-KP
lesions	I-KP
showed	O
that	O
recurrent	O
EM	B-KP
after	O
treatment	O
was	O
due	O
to	O
reinfection	O
rather	O
than	O
a	O
relapse	O
of	O
the	O
previously	O
treated	O
infection	O
[46].\nIn	O
25%	O
of	O
patients	O
with	O
EM,	B-KP
clinical	O
disease	O
resolves	O
but	O
fatigue,	O
cognitive	O
problems,	O
or	O
joint	O
and	O
muscle	O
aches	O
persist	O
at	O
3	O
months	O
after	O
treatment;	O
this	O
percentage	O
decreases	O
to	O
10%	O
at	O
6	O
months.	O
	
Posttreatment	B-KP
Lyme	I-KP
disease	I-KP
syndrome	I-KP
(PTLDS)	B-KP
refers	O
to	O
such	O
symptoms	O
that	O
last	O
for	O
6	O
months	O
after	O
a	O
documented	O
episode	O
of	O
Lyme	O
disease	O
and	O
are	O
disabling.	O
	
The	O
frequency	O
with	O
which	O
PTLDS	I-KP
occurs	O
is	O
believed	O
to	O
be	O
substantially	O
below	O
10%.	O
	
PTLDS	I-KP
should	O
not	O
be	O
confused	O
with	O
"chronic	B-KP
Lyme	I-KP
disease."	O
This	O
name	O
originally	O
referred	O
to	O
late	O
manifestations	O
of	O
the	O
disease,	O
but	O
has	O
been	O
usurped	O
as	O
a	O
label	O
for	O
clinical	O
syndromes	O
that	O
may	O
or	O
may	O
not	O
be	O
associated	O
with	O
previous	O
Lyme	O
borrelia	O
exposure	O
[47].\nThe	O
reasons	O
for	O
persistence	O
of	O
symptoms	O
in	O
some	O
patients	O
after	O
treatment	O
for	O
Lyme	O
disease	O
are	O
not	O
known.	O
	
Theories	O
include	O
residual	O
damage	O
to	O
tissue,	O
slow	O
resolution	O
of	O
the	O
inflammatory	O
state,	O
and/or	O
a	O
form	O
of	O
cytokine-induced	O
sickness	O
behavior	O
due	O
to	O
previously	O
high	O
levels	O
of	O
circulating	O
cytokines.	O
	
Systemic	I-KP
inflammatory	I-KP
cytokines	I-KP
exert	O
adverse	O
effects	O
on	O
neurobehavioral	O
function	O
in	O
other	O
conditions,	O
independent	O
of	O
a	B-KP
central	I-KP
nervous	I-KP
system	I-KP
infection	O
[8].	O
	
Nonspecific	O
symptoms	O
such	O
as	O
fatigue	O
and	O
pain	O
are	O
common	O
in	O
the	O
general	O
population	O
as	O
well.	O
	
Spirochetes	B-KP
with	O
similar	O
morphology,	O
protein	B-KP
profile	I-KP
and	O
antigenic	B-KP
determinants	I-KP
were	O
detected	O
in	O
Ixodes	B-KP
ricinus	I-KP
ticks	I-KP
from	O
Switzerland	O
and	O
Ixodes	B-KP
pacificus	I-KP
ticks	I-KP
from	O
Oregon	O
[7,16]	O
and	O
subsequently	O
in	O
Ixodes	B-KP
persulcatus	I-KP
ticks	I-KP
in	O
Russia	O
[17].	O
	
Genotyping	O
subsequently	O
established	O
that	O
Lyme	B-KP
disease	I-KP
in	O
Europe	O
was	O
caused	O
not	O
only	O
by	O
Bb	B-KP
sensu	I-KP
stricto,	I-KP
but	O
also	O
by	O
two	O
genotypically	O
distinct	O
species,	O
which	O
were	O
named	O
Borrelia	B-KP
afzelii	I-KP
and	O
Borrelia	B-KP
garinii	I-KP
and	O
subsumed	O
under	O
the	O
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
complex	I-KP
(here	O
Borrelia	O
species	O
abbreviated	O
as	O
Borrelia	B-KP
spp.),	O
which	O
now	O
contains	O
at	O
least	O
20	O
confirmed	O
or	O
proposed	O
genomic	O
species	O
(see	O
Table	O
1).	O
	
Of	O
these,	O
Borrelia	B-KP
spielmanii,	I-KP
Borrelia	B-KP
bavariensis,	I-KP
Borrelia	B-KP
bissettii,	I-KP
Borrelia	B-KP
lusitaniae,	I-KP
Borrelia	B-KP
americana,	I-KP
Borrelia	B-KP
andersonii	I-KP
and	O
Borrelia	B-KP
valaisiana	I-KP
also	O
have	O
pathogenic	O
potential	O
(see	O
Table	O
1	O
for	O
the	O
available	O
evidence).	O
	
Of	O
particular	O
note,	O
it	O
had	O
long	O
been	O
held	O
that	O
Bb	B-KP
is	O
the	O
only	O
species	O
causing	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US,	O
but	O
PCR-based	O
detection	O
of	O
both	O
B.	B-KP
	
americana	I-KP
and	O
B.	B-KP
	
andersonii	I-KP
has	O
been	O
reported	O
in	O
blood	B-KP
or	O
skin	B-KP
of	O
a	O
number	O
of	O
US	O
patients,	O
some	O
of	O
them	O
with	O
EM	B-KP
and/or	O
other	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
[18,19].	O
	
In	O
addition,	O
B.	B-KP
	
bissettii,	I-KP
which	O
has	O
been	O
isolated	O
from	O
the	O
cerebral	B-KP
spinal	I-KP
fluid	I-KP
(CSF)	B-KP
of	O
a	O
European	O
patient	O
with	O
Lyme	I-KP
disease	I-KP
[20],	O
has	O
also	O
been	O
detected	O
by	O
PCR	I-KP
in	O
serum	O
of	O
three	O
Californian	O
subjects,	O
but	O
details	O
on	O
whether	O
this	O
was	O
associated	O
with	O
any	O
disease	O
manifestations	O
are	O
not	O
available	O
[21].	O
	
It	O
should	O
be	O
kept	O
in	O
mind,	O
however,	O
that	O
detection	O
by	O
PCR	I-KP
or	O
even	O
isolation	O
by	O
culture	O
of	O
a	O
particular	O
species	O
of	O
Borrelia	I-KP
does	O
not	O
prove	O
its	O
pathogenicity	O
since	O
it	O
is	O
not	O
uncommon	O
for	O
patients	O
to	O
simultaneously	O
harbor	O
two	O
or	O
more	O
species	O
[22e25].	O
	
While	O
direct	O
PCR	I-KP
of	O
tissue	I-KP
samples	I-KP
appears	O
to	O
be	O
more	O
sensitive	O
than	O
culture-based	I-KP
typing,	O
it	O
does	O
not	O
reliably	O
amplify	O
all	O
strains	O
identified	O
by	O
culture	O
[26].	O
	
Spirochetes	B-KP
with	O
similar	O
morphology,	O
protein	B-KP
profile	I-KP
and	O
antigenic	B-KP
determinants	I-KP
were	O
detected	O
in	O
Ixodes	B-KP
ricinus	I-KP
ticks	I-KP
from	O
Switzerland	O
and	O
Ixodes	B-KP
pacificus	I-KP
ticks	I-KP
from	O
Oregon	O
[7,16]	O
and	O
subsequently	O
in	O
Ixodes	B-KP
persulcatus	I-KP
ticks	I-KP
in	O
Russia	O
[17].	O
	
Genotyping	O
subsequently	O
established	O
that	O
Lyme	B-KP
disease	I-KP
in	O
Europe	O
was	O
caused	O
not	O
only	O
by	O
Bb	B-KP
sensu	I-KP
stricto,	I-KP
but	O
also	O
by	O
two	O
genotypically	O
distinct	O
species,	O
which	O
were	O
named	O
Borrelia	B-KP
afzelii	I-KP
and	O
Borrelia	B-KP
garinii	I-KP
and	O
subsumed	O
under	O
the	O
B.	B-KP
	
burgdorferi	I-KP
sensu	I-KP
lato	I-KP
complex	I-KP
(here	O
Borrelia	O
species	O
abbreviated	O
as	O
Borrelia	B-KP
spp.),	O
which	O
now	O
contains	O
at	O
least	O
20	O
confirmed	O
or	O
proposed	O
genomic	O
species	O
(see	O
Table	O
1).	O
	
Of	O
these,	O
Borrelia	B-KP
spielmanii,	I-KP
Borrelia	B-KP
bavariensis,	I-KP
Borrelia	B-KP
bissettii,	I-KP
Borrelia	B-KP
lusitaniae,	I-KP
Borrelia	B-KP
americana,	I-KP
Borrelia	B-KP
andersonii	I-KP
and	O
Borrelia	B-KP
valaisiana	I-KP
also	O
have	O
pathogenic	O
potential	O
(see	O
Table	O
1	O
for	O
the	O
available	O
evidence).	O
	
Of	O
particular	O
note,	O
it	O
had	O
long	O
been	O
held	O
that	O
Bb	B-KP
is	O
the	O
only	O
species	O
causing	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US,	O
but	O
PCR-based	O
detection	O
of	O
both	O
B.	B-KP
	
americana	I-KP
and	O
B.	B-KP
	
andersonii	I-KP
has	O
been	O
reported	O
in	O
blood	B-KP
or	O
skin	B-KP
of	O
a	O
number	O
of	O
US	O
patients,	O
some	O
of	O
them	O
with	O
EM	B-KP
and/or	O
other	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
[18,19].	O
	
In	O
addition,	O
B.	B-KP
	
bissettii,	I-KP
which	O
has	O
been	O
isolated	O
from	O
the	O
cerebral	B-KP
spinal	I-KP
fluid	I-KP
(CSF)	B-KP
of	O
a	O
European	O
patient	O
with	O
Lyme	I-KP
disease	I-KP
[20],	O
has	O
also	O
been	O
detected	O
by	O
PCR	I-KP
in	O
serum	O
of	O
three	O
Californian	O
subjects,	O
but	O
details	O
on	O
whether	O
this	O
was	O
associated	O
with	O
any	O
disease	O
manifestations	O
are	O
not	O
available	O
[21].	O
	
It	O
should	O
be	O
kept	O
in	O
mind,	O
however,	O
that	O
detection	O
by	O
PCR	I-KP
or	O
even	O
isolation	O
by	O
culture	O
of	O
a	O
particular	O
species	O
of	O
Borrelia	I-KP
does	O
not	O
prove	O
its	O
pathogenicity	O
since	O
it	O
is	O
not	O
uncommon	O
for	O
patients	O
to	O
simultaneously	O
harbor	O
two	O
or	O
more	O
species	O
[22e25].	O
	
While	O
direct	O
PCR	I-KP
of	O
tissue	I-KP
samples	I-KP
appears	O
to	O
be	O
more	O
sensitive	O
than	O
culture-based	I-KP
typing,	O
it	O
does	O
not	O
reliably	O
amplify	O
all	O
strains	O
identified	O
by	O
culture	O
[26].	O
	
It	O
is	O
customary	O
to	O
divide	O
Lyme	B-KP
disease	I-KP
into	O
three	O
stages.	O
	
The	O
“primary	B-KP
lesion”	O
or	O
early	O
localized	O
stage	O
occurs	O
at	O
the	O
site	O
of	O
Borrelia	I-KP
inoculation.	O
	
The	O
infection	O
is	O
manifest	O
as	O
erythema	I-KP
migrans	I-KP
(migrating	O
redness),	O
an	O
erythematous	I-KP
papule	I-KP
that	O
expands	O
centrifugally	O
over	O
days	O
to	O
become	O
a	B-KP
plaque,	O
with	O
or	O
without	O
central	O
clearing	O
(Fig.	O
	
2).	O
	
With	O
the	O
development	O
of	B-KP
EM,	O
the	O
patient	O
may	O
also	O
have	O
constitutional	O
symptoms	O
such	O
as	B-KP
fever,	O
malaise,	O
and	B-KP
headache.	O
	
The	B-KP
skin	I-KP
lesion	O
may	O
have	O
localized	O
pain	O
or	I-KP
pruritus,	O
and	B-KP
regional	I-KP
lymphadenopathy	O
may	O
develop.	O
	
In	O
~20%	O
of	O
untreated	O
subjects,	O
this	O
early	O
stage	O
with	B-KP
EM	O
remains	O
the	O
only	O
manifestation	O
of	I-KP
Lyme	I-KP
disease.	O
	
In	O
the	O
first	O
few	O
weeks	O
after	O
infection,	O
spirochetes	O
can	O
be	O
cultured	O
from	O
blood	O
of	O
up	O
to	O
45%	O
of	O
American	O
patients,	O
indicating	O
that	O
they	O
disseminate	O
via	O
the	O
bloodstream	O
to	O
other	O
tissues	O
[101-103].	O
	
Note,	O
however,	O
that	O
culture	O
isolation	O
from	O
blood	O
is	O
much	O
less	O
frequently	O
achieved	O
in	O
European	O
patients	O
(0.7-7.7%)	O
[104-106],	O
possibly	O
suggesting	O
other	O
routes	O
of	O
dissemination.	O
	
The	B-KP
“secondary	I-KP
lesions”	O
of	I-KP
Borrelia	I-KP
infection,	O
the	O
early	O
disseminated	O
stage,	O
comprises	O
multiple	O
EM	I-KP
lesions,	O
widespread	O
erythematous	I-KP
plaques	O
that	O
are	O
smaller	O
but	O
morphologically	O
similar	O
to	O
the	O
initial	O
lesion.	O
	
The	O
early	O
disseminated	O
stage	O
may	O
also	O
be	O
associated	O
with	B-KP
Lyme	I-KP
neuroborreliosis	O
(LNB),	O
and	I-KP
carditis.	O
	
European	O
patients	O
may	O
also	O
develop	O
a	I-KP
skin	I-KP
lesion	O
called	B-KP
borrelial	I-KP
lymphocytoma	O
during	O
this	O
stage	O
(Fig.	O
	
3).	B-KP
	
The	I-KP
“tertiary	I-KP
skin	O
lesion”	O
of	O
this	O
infection,	O
identified	O
for	O
decades	O
before	O
the	O
association	O
with	I-KP
Borreliawas	O
known,	B-KP
is	I-KP
acrodermatitis	I-KP
chronic	I-KP
atrophicans,	O
a	O
focal	O
area	I-KP
of	I-KP
atrophic	O
skin	O
usually	O
involving	O
an	O
extremity.	B-KP
	
Acordermatitis	I-KP
chronica	I-KP
atrophicans	B-KP
(ACA)	O
is	O
primarily	O
found	O
in	O
Europe,	O
and	O
is	O
most	O
commonly	O
associated	O
with	O
the	O
late	O
disseminated	O
stage,	O
which	O
can	O
also	O
include	O
late	O
neurological	O
manifestations.	O
	
Although	O
LA	O
can	O
occur	O
during	O
the	O
early	O
disseminated	O
stage,	O
it	O
is	O
more	O
commonly	O
observed	O
during	O
the	O
late	O
disseminated	O
stage.	O
	
It	O
is	O
customary	O
to	O
divide	O
Lyme	B-KP
disease	I-KP
into	O
three	O
stages.	O
	
The	O
“primary	B-KP
lesion”	O
or	O
early	O
localized	O
stage	O
occurs	O
at	O
the	O
site	O
of	O
Borrelia	I-KP
inoculation.	O
	
The	O
infection	O
is	O
manifest	O
as	O
erythema	I-KP
migrans	I-KP
(migrating	O
redness),	O
an	O
erythematous	I-KP
papule	I-KP
that	O
expands	O
centrifugally	O
over	O
days	O
to	O
become	O
a	B-KP
plaque,	O
with	O
or	O
without	O
central	O
clearing	O
(Fig.	O
	
2).	O
	
With	O
the	O
development	O
of	B-KP
EM,	O
the	O
patient	O
may	O
also	O
have	O
constitutional	O
symptoms	O
such	O
as	B-KP
fever,	O
malaise,	O
and	B-KP
headache.	O
	
The	B-KP
skin	I-KP
lesion	O
may	O
have	O
localized	O
pain	O
or	I-KP
pruritus,	O
and	B-KP
regional	I-KP
lymphadenopathy	O
may	O
develop.	O
	
In	O
~20%	O
of	O
untreated	O
subjects,	O
this	O
early	O
stage	O
with	B-KP
EM	O
remains	O
the	O
only	O
manifestation	O
of	I-KP
Lyme	I-KP
disease.	O
	
In	O
the	O
first	O
few	O
weeks	O
after	O
infection,	O
spirochetes	O
can	O
be	O
cultured	O
from	O
blood	O
of	O
up	O
to	O
45%	O
of	O
American	O
patients,	O
indicating	O
that	O
they	O
disseminate	O
via	O
the	O
bloodstream	O
to	O
other	O
tissues	O
[101-103].	O
	
Note,	O
however,	O
that	O
culture	O
isolation	O
from	O
blood	O
is	O
much	O
less	O
frequently	O
achieved	O
in	O
European	O
patients	O
(0.7-7.7%)	O
[104-106],	O
possibly	O
suggesting	O
other	O
routes	O
of	O
dissemination.	O
	
The	B-KP
“secondary	I-KP
lesions”	O
of	I-KP
Borrelia	I-KP
infection,	O
the	O
early	O
disseminated	O
stage,	O
comprises	O
multiple	O
EM	I-KP
lesions,	O
widespread	O
erythematous	I-KP
plaques	O
that	O
are	O
smaller	O
but	O
morphologically	O
similar	O
to	O
the	O
initial	O
lesion.	O
	
The	O
early	O
disseminated	O
stage	O
may	O
also	O
be	O
associated	O
with	B-KP
Lyme	I-KP
neuroborreliosis	O
(LNB),	O
and	I-KP
carditis.	O
	
European	O
patients	O
may	O
also	O
develop	O
a	I-KP
skin	I-KP
lesion	O
called	B-KP
borrelial	I-KP
lymphocytoma	O
during	O
this	O
stage	O
(Fig.	O
	
3).	B-KP
	
The	I-KP
“tertiary	I-KP
skin	O
lesion”	O
of	O
this	O
infection,	O
identified	O
for	O
decades	O
before	O
the	O
association	O
with	I-KP
Borreliawas	O
known,	B-KP
is	I-KP
acrodermatitis	I-KP
chronic	I-KP
atrophicans,	O
a	O
focal	O
area	I-KP
of	I-KP
atrophic	O
skin	O
usually	O
involving	O
an	O
extremity.	B-KP
	
Acordermatitis	I-KP
chronica	I-KP
atrophicans	B-KP
(ACA)	O
is	O
primarily	O
found	O
in	O
Europe,	O
and	O
is	O
most	O
commonly	O
associated	O
with	O
the	O
late	O
disseminated	O
stage,	O
which	O
can	O
also	O
include	O
late	O
neurological	O
manifestations.	O
	
Although	O
LA	O
can	O
occur	O
during	O
the	O
early	O
disseminated	O
stage,	O
it	O
is	O
more	O
commonly	O
observed	O
during	O
the	O
late	O
disseminated	O
stage.	O
	
If	O
left	O
untreated,	O
~60%	O
of	O
patients	O
with	O
EM	B-KP
develop	O
brief	O
recurrent	O
episodes	O
of	O
arthritis,	O
often	O
preceded	O
and	O
accompanied	O
by	O
arthralgias	B-KP
and	O
myalgias	B-KP
[4].	O
	
Patients	O
with	O
EM	B-KP
would	O
be	O
treated	O
with	O
antibiotics	B-KP
today	O
and	O
would	O
rarely	O
if	O
ever	O
develop	O
arthritis.	O
	
Therefore,	O
patients	O
diagnosed	O
with	O
LA	B-KP
today	O
must	O
come	O
mainly	O
from	O
those	O
subsets	O
of	O
patients	O
whose	O
EM	B-KP
goes	O
unnoticed	O
or	O
undiagnosed	O
or	O
who	O
do	O
not	O
develop	O
EM	B-KP
or	O
any	O
other	O
typical	O
early	O
manifestations	O
of	O
Lyme	B-KP
disease.	I-KP
	
Approximately	O
one-fourth	O
of	O
adults	O
and	O
between	O
16	O
and	O
37%	O
of	O
children	O
with	O
LA	B-KP
recall	O
a	O
tick	O
bite	O
[172,247-250].	O
	
More	O
importantly,	O
almost	O
30%	O
of	O
adults	O
give	O
a	O
history	O
of	O
EM	B-KP
[172],	O
even	O
in	O
case	O
series	O
recruited	O
within	O
the	O
last	O
decade	O
[247],	O
while	O
the	O
proportion	O
in	O
children	O
has	O
ranged	O
between	O
4	O
and	O
18%	O
in	O
recent	O
cohorts	O
[247,251,252].	O
	
According	O
to	O
data	O
from	O
a	O
large	O
vaccine	B-KP
trial	I-KP
in	O
which	O
participants	O
were	O
very	O
closely	O
monitored,	O
16%	O
of	O
patients	O
with	O
Bb	B-KP
infection	I-KP
have	O
only	O
systemic	B-KP
symptoms	I-KP
(primarily	O
headaches	B-KP
and	O
arthralgias)	B-KP
[253]	O
that	O
would	O
not	O
likely	O
be	O
recognized	O
as	O
Lyme	B-KP
disease	I-KP
by	O
the	O
patient	O
or	O
the	O
treating	O
physician.	O
	
An	O
additional	O
7e11%	O
of	O
the	O
participants	O
show	O
asymptomatic	B-KP
seroconversion	I-KP
[68,254].	O
	
Even	O
under	O
the	O
worst-case	O
scenario	O
that	O
60%	O
of	O
these	O
two	O
patient	O
subgroups	O
develop	O
LA,	B-KP
one	O
would	O
expect	O
arthritis	O
to	O
be	O
the	O
presenting	O
manifestation	O
in	O
only	O
~16%	O
of	O
patients	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US.	O
	
Rather	O
surprisingly,	O
patients	O
with	O
LA	B-KP
continue	O
to	O
represent	O
~30%	O
of	O
the	O
cases	O
reported	O
to	O
the	O
CDC	O
[159].	O
	
In	O
contrast,	O
the	O
observed	O
rate	O
in	O
large	O
case	O
series	O
of	O
adults	O
and	O
children	O
with	O
Lyme	B-KP
disease	I-KP
has	O
been	O
6%	O
[160,161].	O
	
In	O
other	O
words,	O
the	O
majority	O
of	O
cases	O
of	O
LA	B-KP
in	O
the	O
US	O
would	O
seem	O
to	O
be	O
preventable.	O
	
LA	B-KP
constitutes	O
4e8%	O
of	O
cases	O
of	O
Lyme	B-KP
borreliosis	I-KP
in	O
European	O
epidemiological	O
studies	O
[51,53,54,163],	O
although	O
the	O
results	O
of	O
a	O
Swedish	O
study	O
suggest	O
that	O
LA	B-KP
may	O
be	O
underdiagnosed	O
[255].	O
	
While	O
Lyme	B-KP
disease	I-KP
overall	O
affects	O
men	O
and	O
women	O
with	O
similar	O
frequency,	O
up	O
to	O
75%	O
of	O
adults	O
and	O
70%	O
of	O
children	O
with	O
LA	B-KP
are	O
male	O
not	O
only	O
in	O
the	O
US	O
[4,247,248,250,251,256-258],	O
but	O
also	O
in	O
Europe	O
[170,172,249,259,260].	O
	
If	O
left	O
untreated,	O
~60%	O
of	O
patients	O
with	O
EM	B-KP
develop	O
brief	O
recurrent	O
episodes	O
of	O
arthritis,	O
often	O
preceded	O
and	O
accompanied	O
by	O
arthralgias	B-KP
and	O
myalgias	B-KP
[4].	O
	
Patients	O
with	O
EM	B-KP
would	O
be	O
treated	O
with	O
antibiotics	B-KP
today	O
and	O
would	O
rarely	O
if	O
ever	O
develop	O
arthritis.	O
	
Therefore,	O
patients	O
diagnosed	O
with	O
LA	B-KP
today	O
must	O
come	O
mainly	O
from	O
those	O
subsets	O
of	O
patients	O
whose	O
EM	B-KP
goes	O
unnoticed	O
or	O
undiagnosed	O
or	O
who	O
do	O
not	O
develop	O
EM	B-KP
or	O
any	O
other	O
typical	O
early	O
manifestations	O
of	O
Lyme	B-KP
disease.	I-KP
	
Approximately	O
one-fourth	O
of	O
adults	O
and	O
between	O
16	O
and	O
37%	O
of	O
children	O
with	O
LA	B-KP
recall	O
a	O
tick	O
bite	O
[172,247-250].	O
	
More	O
importantly,	O
almost	O
30%	O
of	O
adults	O
give	O
a	O
history	O
of	O
EM	B-KP
[172],	O
even	O
in	O
case	O
series	O
recruited	O
within	O
the	O
last	O
decade	O
[247],	O
while	O
the	O
proportion	O
in	O
children	O
has	O
ranged	O
between	O
4	O
and	O
18%	O
in	O
recent	O
cohorts	O
[247,251,252].	O
	
According	O
to	O
data	O
from	O
a	O
large	O
vaccine	B-KP
trial	I-KP
in	O
which	O
participants	O
were	O
very	O
closely	O
monitored,	O
16%	O
of	O
patients	O
with	O
Bb	B-KP
infection	I-KP
have	O
only	O
systemic	B-KP
symptoms	I-KP
(primarily	O
headaches	B-KP
and	O
arthralgias)	B-KP
[253]	O
that	O
would	O
not	O
likely	O
be	O
recognized	O
as	O
Lyme	B-KP
disease	I-KP
by	O
the	O
patient	O
or	O
the	O
treating	O
physician.	O
	
An	O
additional	O
7e11%	O
of	O
the	O
participants	O
show	O
asymptomatic	B-KP
seroconversion	I-KP
[68,254].	O
	
Even	O
under	O
the	O
worst-case	O
scenario	O
that	O
60%	O
of	O
these	O
two	O
patient	O
subgroups	O
develop	O
LA,	B-KP
one	O
would	O
expect	O
arthritis	O
to	O
be	O
the	O
presenting	O
manifestation	O
in	O
only	O
~16%	O
of	O
patients	O
with	O
Lyme	B-KP
disease	I-KP
in	O
the	O
US.	O
	
Rather	O
surprisingly,	O
patients	O
with	O
LA	B-KP
continue	O
to	O
represent	O
~30%	O
of	O
the	O
cases	O
reported	O
to	O
the	O
CDC	O
[159].	O
	
In	O
contrast,	O
the	O
observed	O
rate	O
in	O
large	O
case	O
series	O
of	O
adults	O
and	O
children	O
with	O
Lyme	B-KP
disease	I-KP
has	O
been	O
6%	O
[160,161].	O
	
In	O
other	O
words,	O
the	O
majority	O
of	O
cases	O
of	O
LA	B-KP
in	O
the	O
US	O
would	O
seem	O
to	O
be	O
preventable.	O
	
LA	B-KP
constitutes	O
4e8%	O
of	O
cases	O
of	O
Lyme	B-KP
borreliosis	I-KP
in	O
European	O
epidemiological	O
studies	O
[51,53,54,163],	O
although	O
the	O
results	O
of	O
a	O
Swedish	O
study	O
suggest	O
that	O
LA	B-KP
may	O
be	O
underdiagnosed	O
[255].	O
	
While	O
Lyme	B-KP
disease	I-KP
overall	O
affects	O
men	O
and	O
women	O
with	O
similar	O
frequency,	O
up	O
to	O
75%	O
of	O
adults	O
and	O
70%	O
of	O
children	O
with	O
LA	B-KP
are	O
male	O
not	O
only	O
in	O
the	O
US	O
[4,247,248,250,251,256-258],	O
but	O
also	O
in	O
Europe	O
[170,172,249,259,260].	O
	
The	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
are	O
routinely	O
treated	O
with	O
antibiotics;	B-KP
therapy	O
hastens	O
the	O
resolution	O
and	O
largely	O
prevents	O
the	O
development	O
of	O
other	O
disease	O
manifestations.	O
	
The	O
classes	O
of	O
antibiotics	B-KP
that	O
have	O
shown	O
the	O
greatest	O
effectiveness	O
against	O
Borrelia	B-KP
spirochetes	I-KP
is	O
b-lactams	B-KP
(in	O
particular	O
cephalosporins)	O
tetracyclines	B-KP
and,	O
to	O
a	O
lesser	O
extent,	O
macrolides.	B-KP
	
The	O
best	O
treatment	O
approach,	O
in	O
particular	O
the	O
duration	O
of	O
therapy,	O
is	O
a	O
matter	O
of	O
ongoing	O
debate.	O
	
It	O
is	O
quite	O
evident	O
that	O
not	O
all	O
patients,	O
and	O
most	O
certainly	O
not	O
all	O
species	O
or	O
strains	O
of	O
Borrelia	B-KP
[113]	O
respond	O
equally	O
to	O
the	O
antibiotics	B-KP
most	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
Lyme	B-KP
disease.	I-KP
	
Based	O
on	O
the	O
available	O
evidence	O
from	O
randomized	B-KP
controlled	I-KP
trials	I-KP
(RCTs),	B-KP
treatment	O
recommendations	O
have	O
been	O
published	O
by	O
the	O
Infectious	O
Diseases	O
Society	O
of	O
America	O
(IDSA)	O
[221],	O
the	O
American	O
Academy	O
of	O
Pediatrics	O
[271],	O
and	O
by	O
a	O
variety	O
of	O
national	O
and	O
supranational	O
associations	O
in	O
Europe	O
[203,272]	O
(www.eucalb.com).	O
	
As	O
the	O
comparison	O
between	O
the	O
guidelines	O
published	O
by	O
the	O
IDSA	O
and	O
the	O
EUCALB	O
in	O
Table	O
4	O
illustrates,	O
the	O
approaches	O
to	O
therapy	O
are	O
largely	O
similar	O
on	O
both	O
sides	O
of	O
the	O
Atlantic,	O
but	O
there	O
are	O
some	O
minor	O
differences	O
in	O
the	O
recommended	O
dosage	O
and	O
treatment	O
duration.	O
	
Note	O
that	O
the	O
International	O
Lyme	O
and	O
Associated	O
Diseases	O
Society	O
has	O
also	O
published	O
guidelines	O
for	O
the	O
management	O
of	O
Lyme	I-KP
disease	I-KP
[273].	O
	
These	O
advocate	O
more	O
aggressive	O
and	O
longer	O
treatment	O
courses	O
for	O
patients	O
with	O
persistent	O
symptoms	O
or	O
refractory	O
disease,	O
but	O
much	O
of	O
the	O
terminology	O
is	O
poorly	O
defined	O
and	O
the	O
cited	O
“evidence”	O
is	O
largely	O
restricted	O
to	O
older	O
studies	O
that	O
support	O
such	O
an	O
approach	O
and	O
ignores	O
much	O
of	O
the	O
other	O
available	O
evidence.	O
	
The	O
results	O
of	O
several	O
RCTs	I-KP
and	O
a	O
large	O
retrospective	O
study	O
do	O
not	O
show	O
any	O
benefit	O
in	O
extending	O
the	O
duration	O
of	O
treatment	O
with	O
doxycycline	I-KP
from	O
10	O
days	O
to	O
15	O
or	O
20	O
days	O
in	O
patients	O
with	O
EM	I-KP
[274-276].	O
	
Retrospectively	O
obtained	O
data	O
suggest	O
a	O
similar	O
conclusion	O
for	O
amoxicillin	I-KP
[276].	O
	
In	O
another	O
double-blind	O
RCT,	O
treatment	O
of	O
patients	O
with	O
disseminated	O
Lyme	I-KP
borreliosis	I-KP
with	O
a	O
3-week	O
course	O
of	O
i.v.	O
	
ceftriaxone	O
followed	O
by	O
100	O
days	O
of	O
amoxicillin	I-KP
did	O
not	O
improve	O
the	O
outcome	O
compared	O
to	O
a	O
3-week	O
course	O
of	O
ceftriaxone	I-KP
alone	O
[277].	O
	
These	O
findings	O
do	O
not	O
exclude	O
that	O
some	O
patients	O
may	O
benefit	O
from	O
longer	O
or	O
more	O
aggressive	O
therapy,	O
but	O
the	O
risk-benefit	O
ratio	O
has	O
to	O
be	O
carefully	O
weighed	O
for	O
each	O
individual	O
patient.	O
	
The	O
manifestations	O
of	O
Lyme	B-KP
disease	I-KP
are	O
routinely	O
treated	O
with	O
antibiotics;	B-KP
therapy	O
hastens	O
the	O
resolution	O
and	O
largely	O
prevents	O
the	O
development	O
of	O
other	O
disease	O
manifestations.	O
	
The	O
classes	O
of	O
antibiotics	B-KP
that	O
have	O
shown	O
the	O
greatest	O
effectiveness	O
against	O
Borrelia	B-KP
spirochetes	I-KP
is	O
b-lactams	B-KP
(in	O
particular	O
cephalosporins)	O
tetracyclines	B-KP
and,	O
to	O
a	O
lesser	O
extent,	O
macrolides.	B-KP
	
The	O
best	O
treatment	O
approach,	O
in	O
particular	O
the	O
duration	O
of	O
therapy,	O
is	O
a	O
matter	O
of	O
ongoing	O
debate.	O
	
It	O
is	O
quite	O
evident	O
that	O
not	O
all	O
patients,	O
and	O
most	O
certainly	O
not	O
all	O
species	O
or	O
strains	O
of	O
Borrelia	B-KP
[113]	O
respond	O
equally	O
to	O
the	O
antibiotics	B-KP
most	O
commonly	O
used	O
in	O
the	O
treatment	O
of	O
Lyme	B-KP
disease.	I-KP
	
Based	O
on	O
the	O
available	O
evidence	O
from	O
randomized	B-KP
controlled	I-KP
trials	I-KP
(RCTs),	B-KP
treatment	O
recommendations	O
have	O
been	O
published	O
by	O
the	O
Infectious	O
Diseases	O
Society	O
of	O
America	O
(IDSA)	O
[221],	O
the	O
American	O
Academy	O
of	O
Pediatrics	O
[271],	O
and	O
by	O
a	O
variety	O
of	O
national	O
and	O
supranational	O
associations	O
in	O
Europe	O
[203,272]	O
(www.eucalb.com).	O
	
As	O
the	O
comparison	O
between	O
the	O
guidelines	O
published	O
by	O
the	O
IDSA	O
and	O
the	O
EUCALB	O
in	O
Table	O
4	O
illustrates,	O
the	O
approaches	O
to	O
therapy	O
are	O
largely	O
similar	O
on	O
both	O
sides	O
of	O
the	O
Atlantic,	O
but	O
there	O
are	O
some	O
minor	O
differences	O
in	O
the	O
recommended	O
dosage	O
and	O
treatment	O
duration.	O
	
Note	O
that	O
the	O
International	O
Lyme	O
and	O
Associated	O
Diseases	O
Society	O
has	O
also	O
published	O
guidelines	O
for	O
the	O
management	O
of	O
Lyme	I-KP
disease	I-KP
[273].	O
	
These	O
advocate	O
more	O
aggressive	O
and	O
longer	O
treatment	O
courses	O
for	O
patients	O
with	O
persistent	O
symptoms	O
or	O
refractory	O
disease,	O
but	O
much	O
of	O
the	O
terminology	O
is	O
poorly	O
defined	O
and	O
the	O
cited	O
“evidence”	O
is	O
largely	O
restricted	O
to	O
older	O
studies	O
that	O
support	O
such	O
an	O
approach	O
and	O
ignores	O
much	O
of	O
the	O
other	O
available	O
evidence.	O
	
The	O
results	O
of	O
several	O
RCTs	I-KP
and	O
a	O
large	O
retrospective	O
study	O
do	O
not	O
show	O
any	O
benefit	O
in	O
extending	O
the	O
duration	O
of	O
treatment	O
with	O
doxycycline	I-KP
from	O
10	O
days	O
to	O
15	O
or	O
20	O
days	O
in	O
patients	O
with	O
EM	I-KP
[274-276].	O
	
Retrospectively	O
obtained	O
data	O
suggest	O
a	O
similar	O
conclusion	O
for	O
amoxicillin	I-KP
[276].	O
	
In	O
another	O
double-blind	O
RCT,	O
treatment	O
of	O
patients	O
with	O
disseminated	O
Lyme	I-KP
borreliosis	I-KP
with	O
a	O
3-week	O
course	O
of	O
i.v.	O
	
ceftriaxone	O
followed	O
by	O
100	O
days	O
of	O
amoxicillin	I-KP
did	O
not	O
improve	O
the	O
outcome	O
compared	O
to	O
a	O
3-week	O
course	O
of	O
ceftriaxone	I-KP
alone	O
[277].	O
	
These	O
findings	O
do	O
not	O
exclude	O
that	O
some	O
patients	O
may	O
benefit	O
from	O
longer	O
or	O
more	O
aggressive	O
therapy,	O
but	O
the	O
risk-benefit	O
ratio	O
has	O
to	O
be	O
carefully	O
weighed	O
for	O
each	O
individual	O
patient.	O
	
